"Drug__r.Drug_Code__c","Diagnosis__c","Hierarchy__c"
"100extrabgts","Changes in drug therapy that may impact blood glucose control (e.g., starting or stopping hypo- or hyperglycemic inducing medications, or drug-to-drug or drug-to-disease interactions)","Primary"
"100extrabgts","Acute illness or comorbidities that may impact blood glucose control","Primary"
"100extrabgts","Other",""
"100extrabgts","Not meeting glycemic targets, as determined by a physician, for 3 months or more","Primary"
"100extrabgts","Occupations where hypoglycemia presents a significant safety risk (e.g., pilots, air traffic controllers, commercial drivers)","Primary"
"100extrabgts","Gestational diabetes","Primary"
"1PPIpant","Gastric ulcer","Primary"
"1PPIpant","Eradication of helicobacter pylori, as part of triple therapy (maximum 14 day approval)","Primary"
"1PPIpant","Reflux esophagitis","Primary"
"1PPIpant","Duodenal ulcer","Primary"
"1PPIpant","Zollinger-Ellison syndrome","Primary"
"1PPIpant","Connective tissue disease (e.g., lupus, scleroderma, crest),","Primary"
"1PPIpant","Gastroesophageal reflux disease (GERD)","Primary"
"1PPIpant","Post-Op Bariatric Surgery (internal criteria) - 6 months approval","Primary"
"1PPIpant","Other","Primary"
"1PPIpant","Barrett's esophagus","Primary"
"1PPIrabe","Gastric ulcer","Primary"
"1PPIrabe","Barrett's esophagus","Primary"
"1PPIrabe","Zollinger-Ellison syndrome","Primary"
"1PPIrabe","Connective tissue disease (e.g., lupus, scleroderma, crest),","Primary"
"1PPIrabe","Eradication of helicobacter pylori, as part of triple therapy (maximum 14 day approval)","Primary"
"1PPIrabe","Other","Primary"
"1PPIrabe","Reflux esophagitis","Primary"
"1PPIrabe","Gastroesophageal reflux disease (GERD)","Primary"
"1PPIrabe","Duodenal ulcer","Primary"
"2PPIesom","Connective tissue disease (e.g., lupus, scleroderma, crest),","Primary"
"2PPIesom","Reflux esophagitis","Primary"
"2PPIesom","Duodenal ulcer","Primary"
"2PPIesom","Eradication of helicobacter pylori, as part of triple therapy (maximum 14 day approval)","Primary"
"2PPIesom","Other",""
"2PPIesom","Zollinger-Ellison syndrome","Primary"
"2PPIesom","Barrett's esophagus","Primary"
"2PPIesom","Gastric ulcer","Primary"
"2PPIesom","Gastroesophageal reflux disease (GERD)","Primary"
"2PPIlans","Eradication of helicobacter pylori, as part of triple therapy (maximum 14 day approval)","Primary"
"2PPIlans","Connective tissue disease (e.g., lupus, scleroderma, crest),","Primary"
"2PPIlans","Barrett's esophagus","Primary"
"2PPIlans","Gastric ulcer","Primary"
"2PPIlans","Duodenal ulcer","Primary"
"2PPIlans","Other","Primary"
"2PPIlans","Zollinger-Ellison syndrome","Primary"
"2PPIlans","Reflux esophagitis","Primary"
"2PPIlans","Gastroesophageal reflux disease (GERD)","Primary"
"2PPIomep","Zollinger-Ellison syndrome","Primary"
"2PPIomep","Eradication of helicobacter pylori, as part of triple therapy (maximum 14 day approval)","Primary"
"2PPIomep","Other",""
"2PPIomep","Gastroesophageal reflux disease (GERD)","Primary"
"2PPIomep","Reflux esophagitis","Primary"
"2PPIomep","Duodenal ulcer","Primary"
"2PPIomep","Gastric ulcer","Primary"
"2PPIomep","Connective tissue disease (e.g., lupus, scleroderma, crest),","Primary"
"2PPIomep","Barrett's esophagus","Primary"
"2PPIpant","Reflux esophagitis","Primary"
"2PPIpant","Zollinger-Ellison syndrome","Primary"
"2PPIpant","Gastric ulcer","Primary"
"2PPIpant","Connective tissue disease (e.g., lupus, scleroderma, crest),","Primary"
"2PPIpant","Eradication of helicobacter pylori, as part of triple therapy (maximum 14 day approval)","Primary"
"2PPIpant","Other","Primary"
"2PPIpant","Previously tried Proton Pump Inhibitors - rabeprazole AND pantoprazole magnesium","Primary"
"2PPIpant","Patient has contraindications to one or more 1st line PPIs","Primary"
"2PPIpant","Duodenal ulcer","Primary"
"2PPIpant","Gastroesophageal reflux disease (GERD)","Primary"
"2PPIpant","Barrett's esophagus","Primary"
"abatacept","Rheumatoid Arthritis","Primary"
"abatacept","Polyarticular Juvenile Idiopathic Arthritis (pJIA)","Primary"
"abatacept","Other",""
"abatacept","Renewal 1 year","Secondary"
"abatacept","Indefinite Coverage","Secondary"
"abatacept","Renewal 3 years","Secondary"
"abatacept","Initial","Secondary"
"abobotulinum","focal spasticity","Primary"
"abobotulinum","cervical dystonia (spasmodic torticollis) in adults.","Primary"
"abobotulinum","Other","Primary"
"abrocitinib","Initial (6 months)","Secondary"
"abrocitinib","Other","Primary"
"abrocitinib","Atopic dermatitis","Primary"
"abrocitinib","Renewal (1 Year)","Secondary"
"ACEIcapt","Treatment failure on optimal doses of, or intolerance to, ramipril","Primary"
"ACEIcapt","Complex patient requiring medication(s) for co-existing chronic condition(s)","Primary"
"ACEIcapt","Other",""
"ACEIcila","Complex patient requiring medication(s) for co-existing chronic condition(s)","Primary"
"ACEIcila","Other",""
"ACEIcila","Treatment failure on optimal doses of, or intolerance to, ramipril","Primary"
"ACEIdena","Complex patient requiring medication(s) for co-existing chronic condition(s)","Primary"
"ACEIdena","Treatment failure on optimal doses of, or intolerance to, ramipril","Primary"
"ACEIdena","Other",""
"ACEIenap","other",""
"ACEIenap","Complex patient requiring medication(s) for co-existing chronic condition(s)","Primary"
"ACEIenap","Treatment failure on optimal doses of, or intolerance to, ramipril","Primary"
"ACEIfosi","Treatment failure on optimal doses of, or intolerance to, ramipril","Primary"
"ACEIfosi","Other",""
"ACEIfosi","Complex patient requiring medication(s) for co-existing chronic condition(s)","Primary"
"ACEIliso","Treatment failure on optimal doses of, or intolerance to, ramipril","Primary"
"ACEIliso","Complex patient requiring medication(s) for co-existing chronic condition(s)","Primary"
"ACEIliso","Other",""
"ACEIperi","Complex patient requiring medication(s) for co-existing chronic condition(s)","Primary"
"ACEIperi","Other",""
"ACEIperi","Treatment failure on optimal doses of, or intolerance to, ramipril","Primary"
"ACEIquin","Treatment failure on optimal doses of, or intolerance to, ramipril","Primary"
"ACEIquin","Complex patient requiring medication(s) for co-existing chronic condition(s)","Primary"
"ACEIquin","Other",""
"ACEItran","Other",""
"ACEItran","Treatment failure on optimal doses of, or intolerance to, ramipril","Primary"
"ACEItran","Requiring medication(s) for co-existing chronic condition(s)","Primary"
"acetaminophen","Treatment of osteoarthritis only as monotherapy.","Primary"
"acetaminophen","Treatment osteoarthritis as an adjunct to NSAID therapy when additional pain relief is required.","Primary"
"acetaminophen","Other",""
"adalimumab","Renewal","Secondary"
"adalimumab","Non-Infectious Uveitis","Primary"
"adalimumab","Plaque Psoriasis","Primary"
"adalimumab","Moderate to Severe Active Crohn's","Primary"
"adalimumab","Initial","Secondary"
"adalimumab","Rheumatoid Arthritis","Primary"
"adalimumab","Ankylosing Spondylitis","Primary"
"adalimumab","Psoriatic Arthritis","Primary"
"adalimumab","Fistulizing Crohn's","Primary"
"adalimumab","Ulcerative Colitis","Primary"
"adalimumab","Polyarticular Juvenile Idiopathic Arthritis","Primary"
"adalimumab","Hidradentis Suppurativa","Primary"
"adalimumab","Other","Primary"
"ADHDamph","Other",""
"ADHDamph","ADHD with hyperactivity, impulsivity, or inattention that interferes with functioning.","Primary"
"ADHDatom","ADHD with hyperactivity, impulsivity, or inattention that interferes with functioning.","Primary"
"ADHDatom","Other",""
"ADHDlisd","Other",""
"ADHDlisd","ADHD with hyperactivity, impulsivity, or inattention that interferes with functioning and - methylphenidate IR/SR","Primary"
"ADHDlisd","ADHD with hyperactivity, impulsivity, or inattention that interferes with functioning and - dextroamphetamine IR/SR","Primary"
"ADHDlisd","ADHD with hyperactivity, impulsivity, or inattention that interferes with functioning and - other","Primary"
"ADHDmeth","Diagnosis of Attention Deficit Hyperactivity Disorder (ADHD) with hyperactivity, impulsivity, or inattention that interferes with functioning and - other","Primary"
"ADHDmeth","Other",""
"ADHDmeth","ADHD with hyperactivity, impulsivity, or inattention that interferes with functioning and - methylphenidate IR/SR","Primary"
"ADHDmeth","Diagnosis of Attention Deficit Hyperactivity Disorder (ADHD) with hyperactivity, impulsivity, or inattention that interferes with functioning and - dextroamphetamine IR/SR","Primary"
"ADTIdone","Initial - mild to moderate AlzheimerΓÇÖs disease, AlzheimerΓÇÖs disease with a vascular component, AlzheimerΓÇÖs disease with Parkinsonian features (Lewy bodies), or mixed dementia with AlzheimerΓÇÖs disease","Primary"
"ADTIdone","Other",""
"ADTIdone","Renewal -  mild to moderate AlzheimerΓÇÖs disease, AlzheimerΓÇÖs disease with a vascular component, AlzheimerΓÇÖs disease with Parkinsonian features (Lewy bodies), or mixed dementia with AlzheimerΓÇÖs disease","Primary"
"ADTIgala","Other",""
"ADTIgala","Renewal -  mild to moderate AlzheimerΓÇÖs disease, AlzheimerΓÇÖs disease with a vascular component, AlzheimerΓÇÖs disease with Parkinsonian features (Lewy bodies), or mixed dementia with AlzheimerΓÇÖs disease","Primary"
"ADTIgala","Initial switch from Donepezil- mild to moderate AlzheimerΓÇÖs disease, AlzheimerΓÇÖs disease with a vascular component, AlzheimerΓÇÖs disease with Parkinsonian features (Lewy bodies), or mixed dementia with AlzheimerΓÇÖs disease","Primary"
"ADTIriva","Other",""
"ADTIriva","Renewal -  mild to moderate AlzheimerΓÇÖs disease, AlzheimerΓÇÖs disease with a vascular component, AlzheimerΓÇÖs disease with Parkinsonian features (Lewy bodies), or mixed dementia with AlzheimerΓÇÖs disease","Primary"
"ADTIriva","Initial switch from Donepezil- mild to moderate AlzheimerΓÇÖs disease, AlzheimerΓÇÖs disease with a vascular component, AlzheimerΓÇÖs disease with Parkinsonian features (Lewy bodies), or mixed dementia with AlzheimerΓÇÖs disease","Primary"
"afibdaba","AFib DOES NOT MEET criteria -- no AA","Secondary"
"afibdaba","Other","Primary"
"afibdaba","Dabigatran to be co-administered with Paxlovid for maximum of 10 days","Primary"
"afibdaba","Patient has a diagnosis of non-valvular atrial fibrillation","Primary"
"afibdaba","AFib meets criteria AUTO ADJUDICATE","Secondary"
"afliberceptCMPD","None","Primary"
"afliberceptCMPD","Diabetic Macular Degeneration (DME)","Primary"
"afliberceptCMPD","Disease activity is present at 3 consecutive visits after administration of bevacizumab at a minimum of 4 week intervals with no signs of anatomic or functional improvement","Secondary"
"afliberceptCMPD","Clinically significant macular edema secondary to Branch Retinal Vein Occlusion (BRVO) or Central Retinal Vein Occlusion (CRVO)","Primary"
"afliberceptCMPD","The patient experienced intolerance to bevacizumab treatment warranting discontinuation such as loss in visual acuity despite optimal treatment, sustained increase in intraocular pressure, endophthalmitis","Secondary"
"afliberceptCMPD","The patient did not achieve any improvement in their best corrected visual acuity (BCVA) score despite 3 consecutive courses of bevacizumab","Secondary"
"afliberceptCMPD","The patient did not achieve an improvement of at least 15 Early Treatment Diabetes Retinopathy Study (ETDRS) letters despite 6 months of optimal treatment with bevacizumab","Secondary"
"afliberceptCMPD","Other (exceptional request)","Primary"
"afliberceptCMPD","Neovascular (Wet) Age-Related Macular Degeneration (nAMD)","Primary"
"aggrenox","For secondary prevention of cerebrovascular occlusion and embolization in patients who have experienced recurrent TIA OR stroke while receiving ASA alone","Primary"
"aggrenox","Other",""
"alemtuzumab","As monotherapy for the treatment of relapsing-remitting multiple sclerosis","Primary"
"alenalen","Glucocorticoid-induced osteoporosis in patients who are receiving or expected to receive the equivalent dose of 7.5 mg of prednisone per day or greater AND for 90 consecutive days or longer.","Primary"
"alenalen","Other",""
"alenalen","Clinical or radiographically documented fracture due to osteoporosis","Primary"
"alenrise","Glucocorticoid-induced osteoporosis","Primary"
"alenrise","Clinical or radiographically documented fracture due to osteoporosis","Primary"
"alenrise","Other",""
"alitretinoin","For the treatment of severe chronic hand eczema┬á","Primary"
"alitretinoin","Other",""
"alternateCGM","Medtronic CGM system","Primary"
"amifampridine","Patient is between 6 and 17 years of age","Secondary"
"amifampridine","Renewal request","Primary"
"amifampridine","Initial request","Primary"
"amifampridine","Patient is 18 years of age or older","Secondary"
"amifampridine","Other",""
"amlodipinesoln","Renewal request - Confirmation that the patient is not able to swallow amlodipine tablets.","Primary"
"amlodipinesoln","Other",""
"amlodipinesoln","Initial request - For patients with an inability to swallow oral amlodipine tablets due to age or disability (includes J-tube or G-tube patients). Provide supporting details regarding the patientΓÇÖs inability to swallow tablets.","Primary"
"antiemeticgran","Other",""
"antiemeticgran","Prescribed for the prevention and treatment of nausea and vomiting associated with chemotherapy","Primary"
"antiemeticonda","Prevention and treatment of nausea and vomiting associated with chemotherapy","Primary"
"antiemeticonda","Other",""
"antifungalciclo","Other",""
"antifungalciclo","Diagnosis of a fungal infection of the lower extremities - circulatory condition","Primary"
"antifungalciclo","Diagnosis of a fungal infection of the lower extremities - diabetes","Primary"
"antifungalciclo","Diagnosis of a fungal infection of the lower extremities - other","Primary"
"antifungalclio","Other",""
"antifungalclio","Diagnosis of a fungal infection of the lower extremities - diabetes","Primary"
"antifungalclio","Diagnosis of a fungal infection of the lower extremities - circulatory condition","Primary"
"antifungalclio","Diagnosis of a fungal infection of the lower extremities - other","Primary"
"antifungalclot","Diagnosis of a fungal infection of the lower extremities - diabetes","Primary"
"antifungalclot","Diagnosis of a fungal infection of the lower extremities - circulatory condition","Primary"
"antifungalclot","Diagnosis of a fungal infection of the lower extremities - other","Primary"
"antifungalclot","Other",""
"antifungalketo","Diagnosis of a fungal infection of the lower extremities - other","Primary"
"antifungalketo","Diagnosis of a fungal infection of the lower extremities - diabetes","Primary"
"antifungalketo","Diagnosis of a fungal infection of the lower extremities - circulatory condition","Primary"
"antifungalketo","Other",""
"antifungalmico","Diagnosis of a fungal infection of the lower extremities - diabetes","Primary"
"antifungalmico","Diagnosis of a fungal infection of the lower extremities - other","Primary"
"antifungalmico","Other",""
"antifungalmico","Diagnosis of a fungal infection of the lower extremities - circulatory condition","Primary"
"apomorphine","Other",""
"apomorphine","For the acute, intermittent treatment of patients with advanced Parkinson's disease","Primary"
"aprepitant","Other",""
"aprepitant","For the prevention of acute and delayed nausea and vomiting due to highly-emetogenic cancer chemotherapy (HEC).","Primary"
"ARBcand","Other","Primary"
"ARBcand","Patient has experienced intractable cough or angioedema on an ACE-I (checkbox on form)","Primary"
"ARBcand","Patient has experienced┬áangioedema on an ACE-I","Primary"
"ARBcand","Patient has experienced┬áintractable cough on an ACE-I","Primary"
"ARBepro","Patient has experienced┬áangioedema┬áon an Angiotensin Converting Enzyme Inhibitor (ACE-I): ALL reference ARBs must have been unsucessfully tried","Primary"
"ARBepro","Patient has experienced┬áintractable cough┬áon an Angiotensin Converting Enzyme Inhibitor (ACE-I): ALL reference ARBs must have been unsucessfully tried","Primary"
"ARBepro","Patient has experienced intractable cough or angioedema on an ACE-I (checkbox on form)","Primary"
"ARBepro","Other",""
"ARBirbe","Patient has experienced┬áintractable cough","Primary"
"ARBirbe","Other",""
"ARBirbe","Patient has experienced intractable cough or angioedema on an ACE-I (checkbox on form)","Primary"
"ARBirbe","Patient has experienced┬áangioedema","Primary"
"ARBlosa","Patient has experienced intractable cough or angioedema on an ACE-I (checkbox on form)","Primary"
"ARBlosa","Patient has experienced┬áangioedema on an ACE-I","Primary"
"ARBlosa","Patient has experienced┬áintractable cough on an ACE-I","Primary"
"ARBlosa","Other","Primary"
"ARBolme","Patient has experienced┬áangioedema","Primary"
"ARBolme","Patient has experienced intractable cough or angioedema on an ACE-I (checkbox on form)","Primary"
"ARBolme","Other",""
"ARBolme","Patient has experienced┬áintractable cough","Primary"
"ARBtelm","Other","Primary"
"ARBtelm","Patient has experienced angioedema on an ACE-I","Primary"
"ARBtelm","Patient has experienced intractable cough or angioedema on an ACE-I (checkbox on form)","Primary"
"ARBtelm","Patient has experienced intractable cough on an ACE-I","Primary"
"ARBvals","Patient has experienced┬áintractable cough on an ACE-I","Primary"
"ARBvals","Patient has experienced┬áangioedema on an ACE-I","Primary"
"ARBvals","Other","Primary"
"ARBvals","Patient has experienced intractable cough or angioedema on an ACE-I (checkbox on form)","Primary"
"aripiprazoleINJECTION","Patients who are currently receiving a depot antipsychotic PLUS are experiencing significant side effects such as extrapyramidal symptoms (EPS) or tardive dyskinesia (TD)","Primary"
"aripiprazoleINJECTION","Other","Primary"
"aripiprazoleINJECTION","Patients with a history of non-adherence to antipsychotic medications resulting in negative outcomes, such as hospitalizations, risk to self or others (eg. aggression, suicide risk, etc)","Primary"
"aripiprazoleINJECTION","Patients who have tried oral paliperidone or risperidone, or aripiprazole PLUS at least one other antipsychotic agent and are inadequately controlled at maximally-tolerated doses","Primary"
"aripiprazoleORAL","Other psychosis (not dementia related) AND treatment failure or intolerance to at least one other specified anti-psychotic agent","Primary"
"aripiprazoleORAL","Other",""
"aripiprazoleORAL","Schizophrenia AND treatment failure or intolerance to at least one other specified anti-psychotic agent","Primary"
"asenapine","Other",""
"asenapine","Diagnosis of Bipolar I Disorder","Primary"
"atovaquone","PCP prophylaxis","Primary"
"atovaquone","Other","Primary"
"Avonex","As monotherapy for the treatment of relapsing-remitting multiple sclerosis - renewal","Primary"
"Avonex","As monotherapy for the treatment of relapsing-remitting multiple sclerosis - switch","Primary"
"Avonex","As monotherapy for the treatment of relapsing-remitting multiple sclerosis - initial","Primary"
"aztreonam","A deteriorating clinical condition despite treatment with inhaled tobramycin","Primary"
"aztreonam","Other",""
"aztreonam","For the cyclic treatment of chronic Pseudomonas aeruginosa infections in patients┬áwith┬ámoderate to severe cystic fibrosis","Primary"
"baclofen","Severe spasticity due to spinal cord injury","Primary"
"baclofen","Severe spasticity due to multiple sclerosis","Primary"
"baclofen","Other",""
"benefitapix","Other",""
"benefitapix","Regular Benefit (Jan 5th 2023)","Primary"
"benefitdapa","Regular Benefit (Jan 5th 2023)","Primary"
"benefitdapa","Other","Primary"
"benefitleflunomide","Rheumatoid Arthritis","Primary"
"benefitleflunomide","Other",""
"benralizumab","severe eosinophilic asthma","Primary"
"benralizumab","other",""
"benzydamine","For the treatment of mucositis, ulcerative complications of chemotherapy","Primary"
"benzydamine","Immunocompromised patients at risk of mucosal breakdown.","Primary"
"bevacizumab","Hereditary Hemorrhagic Telangiectasia (HHT)","Primary"
"bevacizumab","Other","Primary"
"bimekizumab","Renewal","Secondary"
"bimekizumab","Plaque Psoriasis","Primary"
"bimekizumab","Other",""
"bimekizumab","Initial","Secondary"
"BPHDUTA","Diagnosis of benign prostatic hyperplasia (BPH) PLUS treatment failure and/or intolerance to an alpha blocking agent","Primary"
"BPHDUTA","other",""
"BPHFINA","other",""
"BPHFINA","Diagnosis of benign prostatic hyperplasia (BPH) PLUS treatment failure and/or intolerance to an alpha blocking agent","Primary"
"brex","Other psychosis (not dementia related) AND treatment failure or intolerance to at least one other specified anti-psychotic agent","Primary"
"brex","Other",""
"brex","Schizophrenia AND treatment failure or intolerance to at least one other specified anti-psychotic agent","Primary"
"breztri","Other",""
"breztri","Diagnosis of moderate to very severe COPD with a post-bronchodilator FEV1/FVC < 0.70 AND FEV1 < 80% predicted","Primary"
"brivaracetam","Used as adjunctive therapy for partial onset seizures after at least TWO other anti-epileptic medications have been tried without success; NOT used concurrently with levetiracetam","Primary"
"brivaracetam","other",""
"budcaps","Crohn's disease","Primary"
"budcaps","Lymphocytic Colitis","Primary"
"budcaps","Ulcerative Colitis (UC)","Primary"
"budcaps","Collagenous Colitis","Primary"
"budcaps","Inflammatory Bowel Disease (IBD)","Primary"
"budcaps","Microscopic Colitis","Primary"
"budcaps","Other",""
"budenema","Ulcerative Colitis","Primary"
"budenema","Other",""
"BupNalFilm","Initial","Primary"
"bupre inj","regular benefit March 14, 2023","Primary"
"buprenorphine-naloxone_8mg2mg_LCAexcep","Other","Primary"
"buprenorphine-naloxone_8mg2mg_LCAexcep","Opiate Use Disorder","Primary"
"buprenorphine-naloxone_8mg2mg_LCAexcep","Renewal","Secondary"
"bupropiondepression","Other","Primary"
"bupropiondepression","Depression","Primary"
"cad","Other",""
"cad","diagnosis of CAD and PAD","Primary"
"candesartan4mg","Exceptional approval for 4mg tablets","Primary"
"candesartan4mg","Not Approved for 4mg tablets, Approved for 8, 16, 32mg tablets","Primary"
"carv","Other",""
"carv","A - Concurrent therapy with an Angiotensin Converting Enzyme inhibitor (ACE-I)","Secondary"
"carv","A - For treatment of stable symptomatic congestive heart failure:","Primary"
"carv","Unable to take ACE-I (provide details):","Secondary"
"CCBfelo","Other",""
"CCBfelo","Treatment failure on optimal dose of, or intolerance to, amlodipine","Primary"
"CCBfelo","Complex patient requiring medications for co-existing chronic condition(s)","Primary"
"CCBnife","Complex patient requiring medications for co-existing chronic condition(s)","Primary"
"CCBnife","Treatment failure on optimal dose of, or intolerance to, amlodipine","Primary"
"CCBnife","Other",""
"celecox","Other",""
"celecox","Gout","Primary"
"celecox","Lupus","Primary"
"celecox","Treatment failure on optimal doses of, or intolerance to, both ibuprofen and naproxen.","Primary"
"celecox","Rheumatoid Arthritis","Primary"
"celecox","Psoriatic Arthritis","Primary"
"celecox","Ankylosing Spondylitis","Primary"
"certo","Initial","Secondary"
"certo","Other",""
"certo","Psoriatic Arthritis","Primary"
"certo","Ankylosing Spondylitis","Primary"
"certo","Rheumatoid Arthritis","Primary"
"certo","Renewal 3 years","Secondary"
"certo","Indefinite Renewal","Secondary"
"certo","Renewal 1 year","Secondary"
"cgrpatog","Other",""
"cgrpatog","Diagnosis of chronic migraine","Secondary"
"cgrpatog","Diagnosis of episodic migraine","Secondary"
"cgrpatog","Migraine prevention Initial Request","Primary"
"cgrpatog","Migraine Prevention 2nd or Subsequent renewal","Primary"
"cgrpatog","Migraine prevention First Renewal","Primary"
"cgrpepti","Other",""
"cgrpepti","Diagnosis of episodic migraine","Secondary"
"cgrpepti","Migraine prevention Initial Request","Primary"
"cgrpepti","Migraine prevention First renewal","Primary"
"cgrpepti","Migraine Prevention 2nd or subsequent renewal","Primary"
"cgrpepti","Diagnosis of chronic migraine","Secondary"
"cgrpfrem","Diagnosis of chronic migraine","Secondary"
"cgrpfrem","Other",""
"cgrpfrem","Migraine prevention First renewal","Primary"
"cgrpfrem","Migraine Prevention 2nd or subsequent renewal","Primary"
"cgrpfrem","Migraine prevention Initial Request","Primary"
"cgrpfrem","Diagnosis of episodic migraine","Secondary"
"cgrpgalc","Diagnosis of chronic migraine","Secondary"
"cgrpgalc","Migraine prevention Initial Request","Primary"
"cgrpgalc","Migraine prevention 2nd or subsequent renewal","Primary"
"cgrpgalc","Other",""
"cgrpgalc","Diagnosis of episodic migraine","Secondary"
"cgrpgalc","Migraine prevention First Renewal","Primary"
"chlorambucil","Lupus","Primary"
"chlorambucil","Other",""
"chlorambucil","Vasculitis","Primary"
"chloroquine","Treatment of extraintestinal amebiasis","Primary"
"chloroquine","Lupus","Primary"
"chloroquine","Rheumatoid Arthritis","Primary"
"chloroquine","Other",""
"cinacalcet","Other","Primary"
"cinacalcet","treatment of hypercalcemia caused by Primary Hyperparathyroidism","Primary"
"cinacalcet","NOT APPROVED: Secondary hyperparathyroidism in patients who are on dialysis. Redirect to BCRA","Primary"
"ciproophthcipr","Other",""
"ciproophthcipr","Failure or intolerance to first-line agents (e.g. aminoglycosides)","Primary"
"cladribine","Other","Primary"
"cladribine","As second-line monotherapy for the treatment of relapsing-remitting multiple sclerosis (RRMS) - initial","Primary"
"cladribine","As second-line monotherapy for the treatment of relapsing-remitting multiple sclerosis (RRMS) - renewal","Primary"
"cladribine","Exceptional: As second-line monotherapy for the treatment of relapsing-remitting multiple sclerosis (RRMS) - retreatment","Primary"
"clobazam","Other",""
"clobazam","Treatment of anxiety","Primary"
"codeine","Other","Primary"
"codeine","For pain management in a specified chronic pain diagnosis","Primary"
"codeine","Renewal","Primary"
"codeine","Diagnosis of cancer","Primary"
"compoundedMethadone10mgpermLOAT","Exceptional Opioid Agonist Treatment - first renewal","Primary"
"compoundedMethadone10mgpermLOAT","Exceptional Opioid Agonist Treatment - subsequent indefinite renewal, if stable","Primary"
"compoundedMethadone10mgpermLOAT","Exceptional Opioid Agonist Treatment - initial request","Primary"
"compoundedMethadone10mgpermLOAT","Other","Primary"
"COPDaclid","Other",""
"COPDaclid","Diagnosis of chronic obstructive pulmonary disease (COPD)","Primary"
"COPDaclidform","Diagnosis of moderate to very severe COPD┬╣ with a post-bronchodilator FEV1/FVC < 0.70 AND FEV1 < 80% predicted.┬á","Primary"
"COPDaclidform","Other",""
"COPDflutsalm","Diagnosis of moderate to very severe COPD with a post-bronchodilator FEV1/FVC < 0.70 AND FEV1 < 80% predicted","Primary"
"COPDflutsalm","Other",""
"COPDflutumecvila","Other",""
"COPDflutumecvila","Diagnosis of moderate to very severe COPD with a post-bronchodilator FEV1/FVC < 0.70 AND FEV1 < 80% predicted","Primary"
"COPDflutvila","Diagnosis of moderate to very severe COPD with a post-bronchodilator FEV1/FVC < 0.70 AND FEV1 < 80% predicted","Primary"
"COPDflutvila","Other",""
"COPDglyc","Diagnosis of chronic obstructive pulmonary disease (COPD)┬áAND failureof both tiotropium and umeclidinium","Primary"
"COPDglyc","Other",""
"COPDinda","Other",""
"COPDinda","Diagnosis of COPD with a post-bronchodilator FEV1/FVC < 0.70 AND contraindication or intolerance to a long-acting muscarinic receptor antagonist (LAMAs)","Primary"
"COPDindaglyc","Other",""
"COPDindaglyc","Diagnosis of moderate to very severe COPD┬╣ with a post-bronchodilator FEV1/FVC < 0.70 AND FEV1 < 80% predicted AND inadequate response after minimum of 6 month trial of either LAMA or LABA","Primary"
"COPDsalm","Diagnosis of COPD with a post-bronchodilator FEV1/FVC < 0.70 AND contraindication or intolerance to a long-acting muscarinic receptor antagonist (LAMAs)","Primary"
"COPDsalm","Other",""
"COPDtiop","Other",""
"COPDtiop","Diagnosis of chronic obstructive pulmonary disease (COPD)┬áAND failureof both tiotropium and umeclidinium","Primary"
"COPDtiopolod","Other",""
"COPDtiopolod","Diagnosis of moderate to very severe COPD┬╣ with a post-bronchodilator FEV1/FVC < 0.70 AND FEV1 < 80% predicted AND inadequate response after minimum of 6 month trial of either LAMA or LABA","Primary"
"COPDumecvila","Other",""
"COPDumecvila","Diagnosis of moderate to very severe COPD┬╣ with a post-bronchodilator FEV1/FVC < 0.70 AND FEV1 < 80% predicted AND inadequate response after minimum of 6 month trial of either LAMA or LABA","Primary"
"cyclosporin","Psoriasis of the palms and/or soles severe enough to interfere with daily living or work","Primary"
"cyclosporin","Other",""
"cyclosporin","Nephrotic syndrome","Primary"
"cyclosporin","Treatment failure on topical corticosteroid","Primary"
"cyclosporin","UVB/UVA light therapy is not available","Primary"
"cyclosporin","Ultraviolet-B light or oral or topical methoxsalen plus ultraviolet-A ligh","Primary"
"cyclosporin","Extensive psoriasis involving at least 25% of body surface or having psoriasis area and severity index of at least 12","Primary"
"cyclosporin","Severe ocular inflammatory disease","Primary"
"cyclosporin","Rheumatoid Arthritis","Primary"
"cyclosporin","Topical therapy with corticosteroids","Primary"
"cyproinj","Indication of need to reduce aggressive sexual drive","Primary"
"cyproinj","Other",""
"cyprooral","Other",""
"cyprooral","Indication of need to reduce aggressive sexual drive","Primary"
"cysteamineDrops","For the treatment of corneal cystine crystal deposits in patients with cystinosis (aka ocular cystinosis)","Primary"
"cysteamineDrops","Other",""
"dalteparin","B. - Associated with pregnancy (up to 4 weeks post partum)","Secondary"
"dalteparin","A. - Failure on oral anticoagulant therapy, ie. recurrence (up to 3 months)","Secondary"
"dalteparin","B. - Following total knee replacement surgery (14 days)","Secondary"
"dalteparin","B. - Post-surgery (abdominal or pelvic surgery) for management of malignant tumor, High Risk, Bedrest 4 days or longer (28 days)","Secondary"
"dalteparin","B. - Post-surgery (abdominal or pelvic surgery) for management of malignant tumor, High Risk, Anesthesia longer than 2 hours (28 days)","Secondary"
"dalteparin","B. - Post-surgery (abdominal or pelvic surgery) for management of a malignant tumor (up to 10 days)","Secondary"
"dalteparin","B. - Concurrent lupus anticoagulant syndrome, antiphospholipid syndrome or thrombophilia (3 months)","Secondary"
"dalteparin","B. - Orthopedic surgery for major trauma (up to 10 days)","Secondary"
"dalteparin","Other",""
"dalteparin","B. - Following total hip replacement surgery (35 days)","Secondary"
"dalteparin","B. - Post-surgery (abdominal or pelvic surgery) for management of malignant tumor, High Risk, Previous history of VTE (28 days)","Secondary"
"dalteparin","A. - Treatment of venous thromboembolism","Primary"
"dalteparin","B. - Prophylaxis of venous thromboembolism","Primary"
"dalteparin","C. - Treatment of venous thromboembolism associated with cancer","Primary"
"dalteparin","Continued treatment from acute care for bridging INR (up to 10 days)","Secondary"
"deferprox","Acquired disease","Primary"
"deferprox","Other",""
"deferprox","Congenital disease","Primary"
"defersirox","Congenital disease","Primary"
"defersirox","Acquired disease","Primary"
"defersirox","Other",""
"DEKAs_capsules","Other","Primary"
"DEKAs_capsules","Chronic pediatric cholestasis","Primary"
"denobiosim60","osteoporosis WITH fracture due to osteoporosis AND a contraindication to oral bisphosphonates - immune-mediated hypersensitivity reaction to oral bisphosphonates","Primary"
"denobiosim60","Other",""
"denobiosim60","osteoporosis WITH fracture due to osteoporosis AND a contraindication to oral bisphosphonates - Other","Primary"
"denobiosim60","osteoporosis WITH fracture due to osteoporosis AND a contraindication to oral bisphosphonates - abnormalities of the esophagus which delay esophageal emptying such as stricture or achalasia","Primary"
"denobiosim60","patients with breast cancer who are on aromatase inhibitor therapy","Primary"
"denosacla","osteoporosis WITH fracture due to osteoporosis AND a contraindication to oral bisphosphonates - abnormalities of the esophagus which delay esophageal emptying such as stricture or achalasia","Primary"
"denosacla","osteoporosis WITH fracture due to osteoporosis AND a contraindication to oral bisphosphonates - immune-mediated hypersensitivity reaction to oral bisphosphonates","Primary"
"denosacla","osteoporosis WITH fracture due to osteoporosis AND a contraindication to oral bisphosphonates - other","Primary"
"denosacla","Other",""
"denosprol","osteoporosis WITH fracture due to osteoporosis AND a contraindication to oral bisphosphonates - immune-mediated hypersensitivity reaction to oral bisphosphonates","Primary"
"denosprol","Other",""
"denosprol","osteoporosis WITH fracture due to osteoporosis AND a contraindication to oral bisphosphonates - other","Primary"
"denosprol","osteoporosis WITH fracture due to osteoporosis AND a contraindication to oral bisphosphonates - abnormalities of the esophagus which delay esophageal emptying such as stricture or achalasia","Primary"
"denosprol","patients with breast cancer who are on aromatase inhibitor therapy","Primary"
"desmopressin","Other",""
"desmopressin","Treatment of diabetes insipidus","Primary"
"DexcomCGM","All criteria has been met (all boxes checked) - Renewal coverage (5 years)","Primary"
"DexcomCGM","Other","Primary"
"DexcomCGM","Some criteria not met (missing check boxes) - Initial or Renewal","Primary"
"DexcomCGM","Child on NSS","Secondary"
"DexcomCGM","All criteria has been met (all boxes checked) - Initial coverage (1 year)","Primary"
"diazoxide","SAP hyperinsulinemia","Primary"
"diclo","Rheumatoid Arthritis","Primary"
"diclo","Ankylosing Spondylitis","Primary"
"diclo","Gout","Primary"
"diclo","Lupus","Primary"
"diclo","Other",""
"diclo","Psoriatic Arthritis","Primary"
"diclomiso","Other",""
"diclomiso","Lupus","Primary"
"diclomiso","Gout","Primary"
"diclomiso","Ankylosing Spondylitis","Primary"
"diclomiso","Psoriatic Arthritis","Primary"
"diclomiso","Rheumatoid Arthritis","Primary"
"dienogest","For the management of pelvic pain associated with endometriosis in patients who have failed or who are unable to use combined hormonal contraceptives (CHC's).  (eg. Alesse, Aviane, Min-Ovral, Portia, Marvelon, Apri, Ortho-Cept, etc.)","Primary"
"dienogest","Other",""
"dimethylfumarate","As monotherapy for the treatment of relapsing-remitting multiple sclerosis - renewal","Primary"
"dimethylfumarate","As monotherapy for the treatment of relapsing-remitting multiple sclerosis - switch","Primary"
"dimethylfumarate","As monotherapy for the treatment of relapsing-remitting multiple sclerosis - initial","Primary"
"DOACriva","Pulmonary embolism (PE)","Primary"
"DOACriva","AFib meets criteria AUTO ADJUDICATE","Secondary"
"DOACriva","Other",""
"DOACriva","Non-valvular atrial fibrillation","Primary"
"DOACriva","Deep vein thrombosis (DVT)","Primary"
"DOACriva","AFib DOES NOT MEET criteria -- no AA","Secondary"
"dorzolamide","Diagnosis of ocular hypertension and open-angle glaucoma in patients with a demonstrated allergy to preservative","Primary"
"dorzolamide","Other",""
"DPP4lina","Other","Primary"
"DPP4lina","Type 2 diabetes - Dual therapy of metformin and an insulin","Primary"
"DPP4lina","Type 2 diabetes - Dual therapy of metformin and a sulfonylurea","Primary"
"DPP4lina","Type 2 diabetes - trial of one agent","Primary"
"DPP4saxa","Type 2 diabetes - Dual therapy of metformin and an insulin","Primary"
"DPP4saxa","Type 2 diabetes - trial of one agent","Primary"
"DPP4saxa","Type 2 diabetes - Dual therapy of metformin and a sulfonylurea","Primary"
"DPP4saxa","Other",""
"dronedarone","For long-term rhythm control of atrial fibrillation (AF) who successfully achieved rhythm control on amiodarone, but who have developed intolerable adverse effects to amiodarone (NOT including liver adverse effects)","Primary"
"dronedarone","Other",""
"duloxetine","For the treatment of neuropathic pain","Primary"
"duloxetine","Other",""
"duloxetine","Exceptional coverage - depression and/or anxiety with or without neuropathic pain","Primary"
"duodopa","Patient experiences severe disability despite having tried frequent dosing of levodopa","Primary"
"duodopa","For the management of severe cases of advanced idiopathic Parkinson's Disease","Primary"
"dupilumab","Severe eosinophilic asthma - 6-11 years old","Primary"
"dupilumab","Severe eosinophilic asthma - 12 years old and older","Primary"
"dupilumab","Other","Primary"
"dupilumab","Atopic dermatitis (not approvable)","Primary"
"dupilumab","Eosinophilic esophagitis (not approvable)","Primary"
"edaravone","Initial Request - Diagnosis of probable amyotrophic lateral sclerosis (ALS) or definite ALS","Primary"
"edaravone","Renewal Request","Primary"
"edaravone","Other",""
"enoxaparin","B. - Post-surgery (abdominal or pelvic surgery) for management of malignant tumor, High Risk, Anesthesia longer than 2 hours (28 days)","Secondary"
"enoxaparin","A. - Failure on oral anticoagulant therapy, ie. recurrence (up to 3 months)","Secondary"
"enoxaparin","B. - Post-surgery (abdominal or pelvic surgery) for management of malignant tumor, High Risk, Previous history of VTE (28 days)","Secondary"
"enoxaparin","B. - Concurrent lupus anticoagulant syndrome, antiphospholipid syndrome or thrombophilia (3 months)","Secondary"
"enoxaparin","B. - Associated with pregnancy (up to 4 weeks post partum)","Secondary"
"enoxaparin","C. - Treatment of venous thromboembolism associated with cancer","Primary"
"enoxaparin","B. - Prophylaxis of venous thromboembolism","Primary"
"enoxaparin","A. - Treatment of venous thromboembolism","Primary"
"enoxaparin","B. - Orthopedic surgery for major trauma (up to 10 days)","Secondary"
"enoxaparin","B. - Following total hip replacement surgery (35 days)","Secondary"
"enoxaparin","Other",""
"enoxaparin","B. - Post-surgery (abdominal or pelvic surgery) for management of malignant tumor, High Risk, Bedrest 4 days or longer (28 days)","Secondary"
"enoxaparin","B. - Post-surgery (abdominal or pelvic surgery) for management of a malignant tumor (up to 10 days)","Secondary"
"enoxaparin","B. - Following total knee replacement surgery (14 days)","Secondary"
"enoxaparin","Continued treatment from acute care for bridging INR (up to 10 days)","Secondary"
"entacapone","Other",""
"entacapone","Parkinson's Disease - As adjunct therapy for patients with an inadequate response after alterations of levodopa/carbidopa doses.","Primary"
"entacapone","Other",""
"entecavir","Chronic Hepatitis B","Primary"
"entecavir","Prophylaxis on Immunotherapy","Primary"
"entecavir","Other",""
"Entresto","Other",""
"Entresto","Patient has heart failure with New York Heart Association (NYHA) Class II to III symptoms - despite at least four weeks of treatment at the optimum stable dose of a beta-blocker and other recommended therapies","Primary"
"epclusa","*do not use* 12 weeks: Treatment-naive or treatment-experienced┬╣ with decompensated cirrhosis. With RBV","Primary"
"epclusa","Mixed Genotype","Secondary"
"epclusa","liver transplant recipient","Primary"
"epclusa","lung transplant recipient","Primary"
"epclusa","Unknown/unable to genotype","Secondary"
"epclusa","12 weeks: Treatment-naive or treatment-experienced┬╣ with no cirrhosis or with compensated cirrhosis","Primary"
"epclusa","24 weeks: Treatment-naive or treatment-experienced┬╣ with decompensated cirrhosis (RBV unavailable)","Primary"
"epclusa","Genotype 1","Secondary"
"epclusa","Genotype 3","Secondary"
"epclusa","Genotype 5","Secondary"
"epclusa","Genotype 2","Secondary"
"epclusa","Genotype 6","Secondary"
"epclusa","Genotype 4","Secondary"
"eplerenone","Exceptional last resort coverage for hypertension","Primary"
"eplerenone","Congestive Heart Failure (CHF), preserved LVEF, EF </= 40%","Primary"
"eplerenone","Primary Hyperaldosteronism","Primary"
"epoprostenol","Other",""
"epoprostenol","As monotherapy, for the treatment of WHO/NYHA functional class IV PAH and inadequate response to non-prostanoid therapies","Primary"
"epoprostenol","As monotherapy, for the treatment of WHO/NYHA functional class IV PAH and contraindication to the non-prostanoid therapies","Primary"
"eslicarbazepine","Adjunctive therapy for partial-onset seizures in adults after other medications have been tried without success","Primary"
"eslicarbazepine","Other",""
"estraderm","For indications of menopausal and post-menopausal symptoms - Extreme intolerance to oral preparations","Primary"
"estraderm","For indications of menopausal and post-menopausal symptoms - Diagnosis of severe liver disease","Primary"
"estraderm","For indications of menopausal and post-menopausal symptoms - other","Primary"
"estraderm","Other",""
"etanbiosim","Renewal 3 years","Secondary"
"etanbiosim","Other",""
"etanbiosim","Psoriatic Arthritis","Primary"
"etanbiosim","Plaque Psoriasis","Primary"
"etanbiosim","Indefinite Renewal","Secondary"
"etanbiosim","Rheumatoid Arthritis","Primary"
"etanbiosim","Ankylosing Spondylitis","Primary"
"etanbiosim","Renewal 1 year","Secondary"
"etanbiosim","Initial","Secondary"
"evo","Initial Request - Diagnosis of ""definite"" or ""probable"" Heterozygous Familial Hypercholesterolemia (HeFH) - Genetic testing","Primary"
"evo","Other","Primary"
"evo","Renewal Request - LDL-C is reduced by at least 40% from the LDL prior to treatment with evolocumab","Primary"
"evo","Initial Request - Diagnosis of ""definite"" or ""probable"" Heterozygous Familial Hypercholesterolemia (HeFH) - Dutch Lipid Network criteria","Primary"
"evo","Initial Request - Diagnosis of ""definite"" or ""probable"" Heterozygous Familial Hypercholesterolemia (HeFH) - Simon Broome criteria","Primary"
"ezetimibe","Patient has a diagnosis of hypercholesterolemia, AND had intolerance to at least 2 specified statins.","Primary"
"ezetimibe","Patient has a diagnosis of hypercholesterolemia, AND LDL-C or cholesterol remained high despite treatment with maximally tolerated statin(s).","Primary"
"ezetimibe","Other",""
"febuxostat","Other",""
"febuxostat","For the reduction of serum uric acid levels in patients with gout who demonstrate an immune-mediated hypersensitivity reaction to allopurinol","Primary"
"fent patch","Person who uses non-prescribed opioids, is at risk of harm from the toxic street drug supply, and is not fentanyl-naive","Primary"
"fent patch","Diagnosis of cancer","Primary"
"fent patch","For pain management in a specified chronic pain diagnosis, PLUS unresponsive or intolerant to 2 specified opioids","Primary"
"fent patch","Renewal (for cancer or chronic pain)","Primary"
"fent patch","Exceptional coverage: management of opioid use disorder (OUD)","Primary"
"fent patch","Other","Primary"
"fent tabs","Other","Primary"
"fent tabs","Person who uses non-prescribed opioids, is at risk of harm from
the toxic street drug supply, and is not fentanyl-naive","Primary"
"fent tabs","Renewal (requires review)","Primary"
"fidaxomicin","treatment of C. Difficile - documented allergy","Primary"
"fidaxomicin","treatment of C. Difficile - failure of oral vancomycin AND when retreatment with vancomycin is not an option AND when the patient is at high risk of hospitalization","Primary"
"fidaxomicin","treatment of C. Difficile - severe intolerance to oral vancomycin","Primary"
"fidaxomicin","Other",""
"filgrastim","For rescue of prolonged febrile neutropenia following chemotherapy","Primary"
"filgrastim","Post-BMT to stimulate bone marrow engraftment","Primary"
"filgrastim","For SECONDARY prophylaxis of febrile neutropenia in cancer patients receiving potentially CURATIVE myelosuppressive chemotherapy","Primary"
"filgrastim","For PRIMARY prophylaxis of febrile neutropenia in cancer patients receiving potentially CURATIVE myelosuppressive chemotherapy regimens","Primary"
"filgrastim","Cancer patients undergoing peripheral blood progenitor cell (PBPC) collection and therapy","Primary"
"filgrastim","Post-BMT for rescue of failure to engraft","Primary"
"filgrastim","Other",""
"filgrastim","Myelodysplastic disorders or aplastic anemia awaiting bone marrow transplantation","Primary"
"filgrastim","Chronic benign cyclical neutropenia","Primary"
"finerenone","Patient has both type 2 diabetes (T2D) and chronic kidney disease (CKD) with an estimated glomerular filtration rate (eGFR) of at least 25ml/min/1.73m².","Primary"
"finerenone","Other",""
"fingolimod","other",""
"fingolimod","As second-line monotherapy for the treatment of relapsing-remitting multiple sclerosis","Primary"
"fluconsolids","Exceptions on an individual basis for fungal infections resistant to first-line medications.","Primary"
"fluconsolids","Other",""
"fluconsolids","Immunocompromised patient","Primary"
"FreeStyleLibre","All criteria have been met (all boxes checked) - Initial coverage (1 year)","Primary"
"FreeStyleLibre","Child on NSS","Secondary"
"FreeStyleLibre","Other","Primary"
"FreeStyleLibre","Some criteria not met (missing check boxes) - Initial or Renewal","Primary"
"FreeStyleLibre","All criteria have been met (all boxes checked) - Renewal coverage (5 years)","Primary"
"gabapentin","Other",""
"gabapentin","Diagnosis of Bipolar Disorder","Primary"
"glatiramer","Other","Primary"
"glatiramer","As monotherapy for the treatment of relapsing-remitting multiple sclerosis - renewal","Primary"
"glatiramer","As monotherapy for the treatment of relapsing-remitting multiple sclerosis - initial","Primary"
"glatiramer","As monotherapy for the treatment of relapsing-remitting multiple sclerosis - switch","Primary"
"gliclazide","Treatment failure or intolerance to at least one other sulfonylurea drug (e.g., glyburide, tolbutamide) at adequate doses.","Primary"
"gliclazide","(Internal) Diagnosis of diabetes or indication patient has diabetes (e.g. noted to be on or failed other diabetes drugs insulin etc.).","Primary"
"gliclazide","Other","Primary"
"glucagon","Child is under the age of four","Primary"
"glucagon","For the treatment of hypoglycemia in patients in whom the nasal spray dosage form is not appropriate","Primary"
"golim","renewal","Secondary"
"golim","Other",""
"golim","initial","Secondary"
"golim","Rheumatoid Arthritis","Primary"
"golim","Ankylosing Spondylitis","Primary"
"golim","Psoriatic Arthritis","Primary"
"goserelin","Other",""
"goserelin","Patient has a diagnosis of endometriosis","Primary"
"H2Bcime","Other",""
"H2Bcime","Treatment failure on prescription dose of, or intolerance to, ranitidine","Primary"
"H2Bfamo","Other",""
"H2Bfamo","Treatment failure on prescription dose of, or intolerance to, ranitidine","Primary"
"H2Bniza","Treatment failure on prescription dose of, or intolerance to, ranitidine","Primary"
"H2Bniza","Other",""
"harvoni","Genotype 1","Secondary"
"harvoni","*do not use* 12 weeks: Liver transplant recipients, treatment-naive or treatment-experienced┬▓ with no cirrhosis or with compensated cirrhosis┬╣ (with RBV)","Primary"
"harvoni","8 weeks: Treatment-naive, mono-HCV infected, fibrosis stage < F3 and HCV RNA < 6 million IU/mL (only considered for non-cirrhotic patients)","Primary"
"harvoni","*do not use* 12 weeks: Treatment-naive or treatment-experienced┬▓ with decompensated cirrhosis┬│ (with RBV)","Primary"
"harvoni","24 weeks: Treatment-experienced┬▓ with compensated cirrhosis┬╣","Primary"
"harvoni","12 weeks: Treatment-experienced┬▓ with no cirrhosis","Primary"
"harvoni","24 weeks: Treatment-naive or treatment-experienced┬▓ with decompensated cirrhosis┬│ (RBV unavailable)","Primary"
"harvoni","12 weeks: Liver transplant recipients, treatment-naive or treatment-experienced┬▓ with no cirrhosis or with compensated cirrhosis┬╣ (RBV unavailable)","Primary"
"harvoni","12 weeks: HIV/HCV-1 co-infected, treatment-naive or treatment-experienced┬▓ with no cirrhosis or with compensated cirrhosis┬╣","Primary"
"harvoni","12 weeks: Treatment-naive with no cirrhosis (including advanced fibrosis stage ΓëÑ 3) or with compensated cirrhosis┬╣","Primary"
"humalog","Allergy or intolerance to biosimilar","Primary"
"humalog","Failure, or otherwise less efficacy, using biosimilar","Primary"
"humalog","Other","Primary"
"humalogMIX","Failure, or otherwise less efficacy, using biosimilar","Primary"
"humalogMIX","Allergy or intolerance to biosimilar","Primary"
"humalogMIX","Other","Primary"
"Humira","Polyarticular Juvenile Idiopathic Arthritis","Primary"
"Humira","Psoriatic Arthritis","Primary"
"Humira","Ankylosing Spondylitis","Primary"
"Humira","Other",""
"Humira","Ulcerative Colitis","Primary"
"Humira","Fistulizing Crohn's","Primary"
"Humira","Moderate to Severe Active Crohn's","Primary"
"Humira","Rheumatoid Arthritis","Primary"
"Humira","Hidradenitis Suppurativa","Primary"
"Humira","Plaque Psoriasis","Primary"
"hydromorph50inj","Exceptional coverage: management of opioid use disorder (OUD)","Primary"
"hydromorph50inj","Renewal","Primary"
"hydromorph50inj","Relief of severe pain in patients who require subcutaneously, intravenously or intramuscularly administered opioids in doses or concentrations higher than those usually needed","Primary"
"hydromorph50inj","Other",""
"hydromorphSR","Pain management in a specified chronic pain (including cancer pain) diagnosis AND sustained release preparations of morphine","Primary"
"hydromorphSR","Pain management in a specified chronic pain (including cancer pain) diagnosis AND regular release dosage forms of hydromorphone","Primary"
"hydromorphSR","Exceptional coverage: management of opioid use disorder (OUD)","Primary"
"hydromorphSR","Other","Primary"
"hydromorphSR","Renewal","Primary"
"hydroxyurea","Patient has a diagnosis of pustular psoriasis┬á","Primary"
"hydroxyurea","Other",""
"hydroxyzine","Other",""
"hydroxyzine","For the treatment of anxiety","Primary"
"icat","Initial Request - For the treatment of acute attacks of hereditary angioedema (HAE)┬á- other","Primary"
"icat","Initial Request - For the treatment of acute attacks of hereditary angioedema (HAE)┬á- type II","Primary"
"icat","Initial Request - For the treatment of acute attacks of hereditary angioedema (HAE)┬á- type I","Primary"
"icat","Renewal Request - Patient is limited to a single dose for self-administration per attack","Primary"
"icosapent","other",""
"icosapent","Secondary prevention of established cardiovascular disease","Primary"
"incobot","Other",""
"incobot","For the treatment of post-stroke spasticity of the upper limb","Primary"
"incobot","For the treatment of blepharospasm","Primary"
"incobot","For the treatment of cervical dystonia of a predominantly rotational form (Spasmodic Torticollis)","Primary"
"indapamide","Treatment failure or intolerance to a thiazide diuretic","Primary"
"indapamide","Other",""
"inflix","renewal indefinite","Secondary"
"inflix","Ankylosing Spondylitis","Primary"
"inflix","Psoriatic Arthritis","Primary"
"inflix","initial","Secondary"
"inflix","renewal 1 year","Secondary"
"inflix","renewal 3 years","Secondary"
"inflix","Other",""
"inflix","Hidradenitis Suppurativa","Primary"
"inflix","Plaque Psoriasis","Primary"
"inflix","Moderate to Severe Active Crohn's","Primary"
"inflix","Fistulizing Crohns","Primary"
"inflix","Ulcerative Colitis","Primary"
"inflix","Rheumatoid Arthritis","Primary"
"INRtestingdevice","other","Primary"
"INRtestingdevice","Renewal request (6 months, strips only)","Primary"
"INRtestingdevice","Initial request (6 months, device + strips)","Primary"
"interferonA","Chronic Hepatitis B, non-cirrhosis","Primary"
"interferonA","Other",""
"interferonB1B","As monotherapy for the treatment of relapsing-remitting multiple sclerosis - initial","Primary"
"interferonB1B","As monotherapy for secondary progressive multiple sclerosis (SPMS) - initial","Primary"
"interferonB1B","As monotherapy for secondary progressive multiple sclerosis (SPMS) - switch","Primary"
"interferonB1B","As monotherapy for secondary progressive multiple sclerosis (SPMS) - renewal","Primary"
"interferonB1B","As monotherapy for the treatment of relapsing-remitting multiple sclerosis - renewal","Primary"
"interferonB1B","As monotherapy for the treatment of relapsing-remitting multiple sclerosis - switch","Primary"
"ironisomaltoside","Patient is intolerant to at least TWO specified oral iron therapies","Secondary"
"ironisomaltoside","Patient has a contraindication to oral iron therapy (clinical malabsorption, severe and/or chronic blood loss)","Secondary"
"ironisomaltoside","Other",""
"ironisomaltoside","Patient has failed to respond to an adequate trial (minimum of 4 weeks) of at least one oral iron therapy","Secondary"
"ironisomaltoside","Diagnosis of Iron Deficiency Anemia (IDA) AND iron isomatoside will be administered where appropriate monitoring and management of hypersensitivity reactions can be provided","Primary"
"ironsucrose","Patient has failed to respond to an adequate trial (minimum of 4 weeks) of at least one oral iron therapy","Secondary"
"ironsucrose","Patient has a contraindication to oral iron therapy (clinical malabsorption, severe and/or chronic blood loss)","Secondary"
"ironsucrose","Diagnosis of Iron Deficiency Anemia (IDA) AND iron sucrose will be administered where appropriate monitoring and management of hypersensitivity reactions can be provided","Primary"
"ironsucrose","Patient is intolerant to at least TWO specified oral iron therapies","Secondary"
"ironsucrose","Other",""
"isavuconazole","Other",""
"isavuconazole","For the treatment of Invasive Mucormycosis (IM) in adults when prescribed by infectious disease specialist and if a patient is established on isavuconazole in hospital","Primary"
"ismn","Experienced treatment failure on optimal dose of isosorbide dinitrate (ISDN)","Primary"
"ismn","Other",""
"ismn","Diagnosis of unstable angina","Primary"
"ismn","Experienced intolerance to isosorbide dinitrate (ISDN)","Primary"
"itraconazole","Pulse treatment for severe onychomycosis with functional disability","Primary"
"itraconazole","Other","Primary"
"itraconazole","Immunocompromised patient","Primary"
"ivabradine","Patient has stable heart failure with New York Heart Association Class II or III symptoms","Primary"
"ivabradine","NYHA class II or III symptoms that have persisted despite at least four weeks of treatment at the optimum stable dose of a B-blocker, an aldosterone antagonist AND an ACEI or an ARB","Primary"
"ivabradine","Other",""
"ixekiz","initial","Secondary"
"ixekiz","renewal","Secondary"
"ixekiz","Psoriatic Arthritis (PsA)","Primary"
"ixekiz","Other",""
"ixekiz","Plaque Psoriasis (PP)","Primary"
"ketamine10","Other",""
"ketamine50","Other",""
"LABAflutsalm","Other",""
"LABAflutsalm","Diagnosis of asthma┬áAND inadequate response on optimal dose of inhaled corticosteroid.","Primary"
"LABAflutvila","Diagnosis of asthma┬áAND inadequate response on optimal dose of inhaled corticosteroid.","Primary"
"LABAflutvila","Other",""
"LABAform","Diagnosis of asthma┬áAND inadequate response on optimal dose of inhaled corticosteroid.","Primary"
"LABAform","Other",""
"LABAformbude","Diagnosis of asthma┬áAND inadequate response on optimal dose of inhaled corticosteroid.","Primary"
"LABAformbude","Other",""
"LABAformmom","Other",""
"LABAformmom","Diagnosis of asthma┬áAND inadequate response on optimal dose of inhaled corticosteroid.","Primary"
"LABAindamome","Diagnosis of asthma AND inadequate response on optimal dose of inhaled corticosteroid.","Primary"
"LABAindamome","Other",""
"LABAindamomeglyco","Other",""
"LABAindamomeglyco","Diagnosis of asthma AND inadequate response on optimal dose of inhaled corticosteroid AND experienced one or more exacerbations in the past 12 months","Primary"
"LABAsalm","Diagnosis of asthma AND inadequate response on optimal dose of inhaled corticosteroid","Primary"
"LABAsalm","Other",""
"lacolaco","Status epilepticus (exceptional)","Primary"
"lacolaco","Other","Primary"
"lacolaco","Generalized seizures (exceptional)","Primary"
"lacolaco","Partial onset seizures","Primary"
"lactulose","Treatment of liver failure","Primary"
"lactulose","Treatment of portal systemic encephalopathy","Primary"
"lactulose","Other",""
"LAinsulinbasa","Patient is currently taking NPH insulin (and/or pre-mix insulin) and has experienced or continues to experience severe, systemic or local allergic reaction to existing insulin treatment","Primary"
"LAinsulinbasa","Patient is currently taking NPH insulin (and/or pre-mix insulin) and has experienced unexplained nocturnal hypoglycemia at least once a month despite optimal management","Primary"
"LAinsulinbasa","Other",""
"LAinsulinbasa","Patient has a contraindication to NPH insulin","Primary"
"Lainsulindete","Patient is currently taking NPH insulin (and/or pre-mix insulin) and has experienced or continues to experience severe, systemic or local allergic reaction to existing insulin treatment","Primary"
"Lainsulindete","Patient is currently taking NPH insulin (and/or pre-mix insulin) and has experienced unexplained nocturnal hypoglycemia at least once a month despite optimal management","Primary"
"Lainsulindete","Other",""
"Lainsulindete","Patient has a contraindication to NPH insulin","Primary"
"lamivudine","Other - Hepatitis B reactivation prophylaxis while on immunosuppressants","Primary"
"lamivudine","Other",""
"lamivudine","Chronic Hepatitis B","Primary"
"LBMdiph","Other",""
"LBMdiph","For the treatment of diarrhea due to a specified chronic illness","Primary"
"letermovir","Patient at high risk of CMV infection AND has an undetectable CMV DNA at baseline","Primary"
"letermovir","Other","Primary"
"leuprolide","Diagnosis of endometriosis","Primary"
"leuprolide","Diagnosis indicating need to reduce sexual drive","Primary"
"leuprolide","Other",""
"leuprolide","Diagnosis of precocious puberty","Primary"
"levetiracetam solution","Diagnosis of epilepsy/seizures, unable to swallow tablets, AND currently on levetiracetam and is benefitting (e.g. put on in hospital, started by a neurologist, etc)","Primary"
"levetiracetam solution","Diagnosis of epilepsy/seizures, unable to swallow tablets, AND treatment failure on at least ONE anti-seizure medication","Primary"
"levetiracetam solution","Renewal of coverage for levetiracetam liquid, confirming patient is still unable to swallow tablets.","Primary"
"levetiracetam solution","Other",""
"levetiracetam tablet","Other",""
"levetiracetam tablet","Diagnosis of epilepsy AND currently on levetiracetam and is benefitting (e.g. put on in hospital, started by a neurologist, etc)","Primary"
"levetiracetam tablet","Diagnosis of epilepsy","Primary"
"linezolid","Other",""
"linezolid","Treatment of methicillin-resistant staphylococcus aureus (MRSA) in patients who are unresponsvie to or intolerant of injectable vancomycin","Primary"
"linezolid","Treatment of vancomycin resistant enterococcus (VRE) infections","Primary"
"loperamide","For the treatment of diarrhea due to a specified chronic illness","Primary"
"loperamide","Other",""
"lovenox","other","Primary"
"lovenox","exceptional brand request","Primary"
"lurasidone","other psychosis","Primary"
"lurasidone","schizophrenia","Primary"
"lurasidone","bipolar disorder","Primary"
"lurasidone","Other","Primary"
"luspatercept","Initial Request","Primary"
"luspatercept","Other",""
"luspatercept","Renewal Request","Primary"
"Maintenapalisust","For management of manifestations of related psychotic disorders (not dementia-related) - are currently receiving a conventional depot antispychotic PLUS experiencing significant side effects such as extrapyramidal symptoms or tardive dyskinesia","Primary"
"Maintenapalisust","For management of manifestations of related psychotic disorders (not dementia-related) - with a history of non-adherence to antipsychotic medications resulting in important negative outcomes such as repeated hospitalizations","Primary"
"Maintenapalisust","Other",""
"Maintenapalisust","For management of manifestations of related psychotic disorders (not dementia-related) - have tried oral aripiprazole, risperidone, or paliperidone PLUS at least one other antipsychotic agent AND continues to be inadequately controlled","Primary"
"Maintenapalisust","For management of manifestations of schizophrenia","Primary"
"Maintenapalitrin","For management of manifestations of related psychotic disorders (not dementia-related) - are currently receiving a conventional depot antispychotic PLUS experiencing significant side effects such as extrapyramidal symptoms or tardive dyskinesia","Primary"
"Maintenapalitrin","For management of manifestations of related psychotic disorders (not dementia-related) - have tried oral aripiprazole, risperidone, or paliperidone PLUS at least one other antipsychotic agent AND continues to be inadequately controlled","Primary"
"Maintenapalitrin","Other",""
"Maintenapalitrin","For management of manifestations of schizophrenia","Primary"
"Maintenapalitrin","For management of manifestations of related psychotic disorders (not dementia-related) - with a history of non-adherence to antipsychotic medications resulting in important negative outcomes such as repeated hospitalizations","Primary"
"Maintenarisp","For management of manifestations of related psychotic disorders (not dementia-related) - are currently receiving a conventional depot antispychotic PLUS experiencing significant side effects such as extrapyramidal symptoms or tardive dyskinesia","Primary"
"Maintenarisp","For management of manifestations of related psychotic disorders (not dementia-related) - history of non-adherence to antipsychotic medications resulting in important negative outcomes such as repeated hospitalizations","Primary"
"Maintenarisp","Other",""
"Maintenarisp","For management of manifestations of related psychotic disorders (not dementia-related) - have tried oral aripiprazole, risperidone, or paliperidone PLUS at least one other antipsychotic agent AND continues to be inadequately controlled","Primary"
"Maintenarisp","For management of manifestations of schizophrenia","Primary"
"maribavir","Treatment of CMV - Renewal","Primary"
"maribavir","Treatment of CMV - Initial","Primary"
"maribavir","Treatment of CMV - Recurrence","Primary"
"mavacamten","Other",""
"mavacamten","Renewal Request","Primary"
"mavacamten","Initial Request","Primary"
"maviretadult","Genotype 1 - Treatment-naive with no cirrhosis or with compensated cirrhosis","Primary"
"maviretadult","heart transplant recipient","Primary"
"maviretadult","Genotype 3 - Treatment-experienced with no cirrhosis or with compensated cirrhosis","Primary"
"maviretadult","Genotype 1 - Treatment-experienced with no cirrhosis","Primary"
"maviretadult","Genotype 3 - Treatment-naive with no cirrhosis or with compensated cirrhosis","Primary"
"maviretadult","Genotype 1 - Treatment-experienced with compensated cirrhosis","Primary"
"maviretadult","Genotype 1 - Previously treated with an NS5A inhibitor-containing regimen, but NS3/4A protease inhibitor treatment-naive","Primary"
"maviretadult","Genotype 1 - Previously treated with an NS3/4A protease inhibitor-containing regimen, but NS5A inhibitor treatment-naive","Primary"
"maviretadult","Genotype 2,4,5,6 - Treatment-naive with no cirrhosis or with compensated cirrhosis","Primary"
"maviretadult","Genotype 2,4,5,6 - Treatment-experienced with no cirrhosis","Primary"
"maviretadult","Unable to Verify Genotype","Primary"
"maviretadult","kidney transplant recipient","Primary"
"maviretadult","Genotype 2,4,5,6 - Treatment-experienced with compensated cirrhosis","Primary"
"maviretpediatric","Genotype 2,4,5,6 - Treatment-naive with no cirrhosis or with compensated cirrhosis","Primary"
"maviretpediatric","Genotype 2,4,5,6 - Treatment-experienced with no cirrhosis","Primary"
"maviretpediatric","Genotype 1 - Treatment-experienced with compensated cirrhosis","Primary"
"maviretpediatric","Unable to Verify Genotype","Primary"
"maviretpediatric","Genotype 3 - Treatment-naive with no cirrhosis or with compensated cirrhosis","Primary"
"maviretpediatric","Genotype 1 - Treatment-experienced with no cirrhosis","Primary"
"maviretpediatric","Genotype 3 - Treatment-experienced with no cirrhosis or with compensated cirrhosis","Primary"
"maviretpediatric","kidney transplant recipient","Primary"
"maviretpediatric","Genotype 1 - Treatment-naive with no cirrhosis or with compensated cirrhosis","Primary"
"maviretpediatric","Genotype 2,4,5,6 - Treatment-experienced with compensated cirrhosis","Primary"
"maviretpediatric","heart transplant recipient","Primary"
"meloxicam","Gout","Primary"
"meloxicam","Lupus","Primary"
"meloxicam","Treatment failure on optimal doses of, or intolerance to, both ibuprofen and naproxen","Primary"
"meloxicam","Ankylosing Spondylitis","Primary"
"meloxicam","Psoriatic Arthritis","Primary"
"meloxicam","Rheumatoid Arthritis","Primary"
"meloxicam","Other",""
"mepolizumab","other",""
"mepolizumab","severe eosinophilic asthma","Primary"
"mercaptopurine","Inflammatory bowel disease","Primary"
"mercaptopurine","Autoimmune hepatitis","Primary"
"mercaptopurine","Ulcerative Colitis","Primary"
"mercaptopurine","Other",""
"mercaptopurine","Crohn's disease","Primary"
"methadone_tablets","For pain in extenuating circumstances preventing dose measurement with 10mg/ml or 1 mg/ml solution","Primary"
"methadone_tablets","Other","Primary"
"methotrexatePFsyringe","Treatment of rheumatoid arthritis, when the patient demonstrates failure on or intolerance to oral methotrexate, and they are unable to handle or use vials.","Primary"
"methotrexatePFsyringe","Other",""
"methotrexateVial","Other",""
"methotrexateVial","Treatment of rheumatoid arthritis, when the patient demonstrates failure on or intolerance to oral methotrexate","Primary"
"miniMed","Other form of diabetes (please specify):","Primary"
"miniMed","Type 1 diabetes","Primary"
"mirabegron","Initial (1 year)","Primary"
"mirabegron","Renewal (indefinite)","Primary"
"mirikizumab","Ulcerative Colitis - Renewal","Primary"
"mirikizumab","Ulcerative Colitis - Initial","Primary"
"mirikizumab","Other",""
"mmf","Bullous pemphigoid","Primary"
"mmf","Other",""
"mmf","Autoimmune hepatitis","Primary"
"modafinil","Other",""
"modafinil","Treatment of narcolepsy","Primary"
"mometNS","Diagnosis of allergic rhinitis in child 3-11 years old","Primary"
"mometNS","Other",""
"montelukast","Other","Primary"
"nabumetone","Other",""
"nabumetone","Rheumatoid Arthritis","Primary"
"nabumetone","Psoriatic Arthritis","Primary"
"nabumetone","Ankylosing Spondylitis","Primary"
"nabumetone","Gout","Primary"
"nabumetone","Lupus","Primary"
"nabumetone","Treatment failure on optimal doses of or intolerance to , ALL of the following: ibuprofen, naproxen (regular release), diclofenac, AND either celecoxib or meloxicam","Primary"
"nadroparin","B. - Following total hip replacement surgery (35 days)","Secondary"
"nadroparin","Other",""
"nadroparin","Continued treatment from acute care for bridging INR (up to 10 days)","Secondary"
"nadroparin","B. - Following total knee replacement surgery (14 days)","Secondary"
"nadroparin","A. - Failure on oral anticoagulant therapy, ie. recurrence (up to 3 months)","Secondary"
"nadroparin","B. - Orthopedic surgery for major trauma (up to 10 days)","Secondary"
"nadroparin","A. - Treatment of venous thromboembolism","Primary"
"nadroparin","B. - Prophylaxis of venous thromboembolism","Primary"
"nadroparin","B. - Associated with pregnancy (up to 4 weeks post partum)","Secondary"
"nadroparin","B. - Concurrent lupus anticoagulant syndrome, antiphospholipid syndrome or thrombophilia (3 months)","Secondary"
"naproEC","Rheumatoid Arthritis","Primary"
"naproEC","Ankylosing Spondylitis","Primary"
"naproEC","Gout","Primary"
"naproEC","Lupus","Primary"
"naproEC","Psoriatic Arthritis","Primary"
"naproEC","Other",""
"naproEC","Treatment failure on optimal dose, or intolerance to, at least one of enteric-coated ASA, ibuprofen, or naproxen","Primary"
"natalizumab","other",""
"natalizumab","As second-line monotherapy for the treatment of relapsing-remitting multiple sclerosis","Primary"
"nebulesbude","Resident of a long-term facility PLUS regularly requires the administration of three or more inhaled medications at least three times daily","Primary"
"nebulesbude","Person who has difficulty in generating adequate inspiratory effort that he/she is unable to achieve therapeutic benefit from an inhaler with an aerochamber.","Primary"
"nebulesbude","Person who has cognitive impairment PLUS has had an unsuccessful trial in the use of an inhaler attached to an aerochamber with a mouthpiece","Primary"
"nebulesbude","Person who is living independently PLUS either suffers from severe upper extremity disability or lacks fine motor coordination","Primary"
"nebulesbude","Diagnosis of Rhinosinusitis With Polyps (Internal Criteria)","Primary"
"nebulesbude","Diagnosis of Rhinosinusitis Without Polyps (Internal Criteria)","Primary"
"nebulesbude","Other","Primary"
"nebulescrom","Resident of a long-term facility PLUS regularly requires the administration of three or more inhaled medications at least three times daily","Primary"
"nebulescrom","Other",""
"nebulescrom","Person who has cognitive impairment PLUS has had an unsuccessful trial in the use of an inhaler attached to an aerochamber with a mouthpiece","Primary"
"nebulescrom","Person who is living independently PLUS either suffers from severe upper extremity disability or lacks fine motor coordination to a degree that precludes effective inhaler techniques even when aided by inhaler-assistance devices","Primary"
"nebulescrom","Person who has difficulty in generating adequate inspiratory effort that he/she is unable to achieve therapeutic benefit from an inhaler with an aerochamber.","Primary"
"nebulesipra","Person who is living independently PLUS either suffers from severe upper extremity disability or lacks fine motor coordination to a degree that precludes effective inhaler techniques even when aided by inhaler-assistance devices","Primary"
"nebulesipra","Resident of a long-term facility PLUS regularly requires the administration of three or more inhaled medications at least three times daily","Primary"
"nebulesipra","Person who has difficulty in generating adequate inspiratory effort that he/she is unable to achieve therapeutic benefit from an inhaler with an aerochamber","Primary"
"nebulesipra","Other",""
"nebulesipra","Person who has cognitive impairment PLUS has had an unsuccessful trial in the use of an inhaler attached to an aerochamber with a mouthpiece","Primary"
"nebulesiprasalb","Person who has cognitive impairment PLUS has had an unsuccessful trial in the use of an inhaler attached to an aerochamber with a mouthpiece","Primary"
"nebulesiprasalb","Person who is living independently PLUS either suffers from severe upper extremity disability or lacks fine motor coordination to a degree that precludes effective inhaler techniques even when aided by inhaler-assistance devices","Primary"
"nebulesiprasalb","Person who has difficulty in generating adequate inspiratory effort that he/she is unable to achieve therapeutic benefit from an inhaler with an aerochamber","Primary"
"nebulesiprasalb","Other",""
"nebulesiprasalb","Resident of a long-term facility PLUS regularly requires the administration of three or more inhaled medications at least three times daily","Primary"
"nebulessalb","Person who has cognitive impairment PLUS has had an unsuccessful trial in the use of an inhaler attached to an aerochamber with a mouthpiece","Primary"
"nebulessalb","Person who is living independently PLUS either suffers from severe upper extremity disability or lacks fine motor coordination to a degree that precludes effective inhaler techniques even when aided by inhaler-assistance devices","Primary"
"nebulessalb","Resident of a long-term facility PLUS regularly requires the administration of three or more inhaled medications at least three times daily","Primary"
"nebulessalb","Person who has difficulty in generating adequate inspiratory effort that he/she is unable to achieve therapeutic benefit from an inhaler with an aerochamber.","Primary"
"nebulessalb","Other",""
"netupitant","For the prevention of acute and delayed nausea and vomiting due to highly-emetogenic cancer chemotherapy in combination with dexamethasone","Primary"
"netupitant","Other",""
"nintedanib","progressive pulmonary fibrosis (PPF)","Primary"
"nintedanib","renewal (1 year)","Secondary"
"nintedanib","initial (7 months)","Secondary"
"nintedanib","mild to moderate idiopathic pulmonary fibrosis (IPF)","Primary"
"nintedanib","Other","Primary"
"nitisinone","hereditary tyrosinemia type 1 (HT-1) - for patients identified through prenatal genetic testing","Primary"
"nitisinone","hereditary tyrosinemia type 1 (HT-1) - for patients identified through newborn screening","Primary"
"no_limit_bgts","Gestational Diabetes","Primary"
"no_limit_bgts","Other","Primary"
"novomix","Allergy or intolerance to biosimilar","Primary"
"novomix","Other","Primary"
"novomix","Failure, or otherwise less efficacy, using biosimilar","Primary"
"NRT","Patient filled later than Oct 1, and termination date spilled over into current year - End of Year approval (28 days supply)","Primary"
"NRT","Other","Primary"
"NRT","Patients MSP did not autogenerate new NRT coverage on Jan 1 of current year - 3 Month approval (28 days supply)","Primary"
"NRT","Patient has missed a fill and is within 21 days of expiry from PharmaNet -7 Day approval (28 days supply)","Primary"
"NSAIDdiflu","Lupus","Primary"
"NSAIDdiflu","Gout","Primary"
"NSAIDdiflu","Ankylosing Spondylitis","Primary"
"NSAIDdiflu","Psoriatic Arthritis","Primary"
"NSAIDdiflu","Rheumatoid Arthritis","Primary"
"NSAIDdiflu","Other",""
"NSAIDflur","Treatment failure on optimal doses of or intolerance to , ALL of the following: ibuprofen, naproxen (regular release), diclofenac, AND either celecoxib or meloxicam","Primary"
"NSAIDflur","Rheumatoid Arthritis","Primary"
"NSAIDflur","Psoriatic Arthritis","Primary"
"NSAIDflur","Ankylosing Spondylitis","Primary"
"NSAIDflur","Diagnosis of gout","Primary"
"NSAIDflur","Lupus","Primary"
"NSAIDflur","Other",""
"NSAIDindo","Ankylosing Spondylitis","Primary"
"NSAIDindo","Psoriatic Arthritis","Primary"
"NSAIDindo","Gout","Primary"
"NSAIDindo","Lupus","Primary"
"NSAIDindo","Treatment failure on optimal doses of or intolerance to , ALL of the following: ibuprofen, naproxen (regular release), diclofenac, AND either celecoxib or meloxicam","Primary"
"NSAIDindo","Rheumatoid Arthritis","Primary"
"NSAIDindo","Other",""
"NSAIDketo","Psoriatic Arthritis","Primary"
"NSAIDketo","Rheumatoid Arthritis","Primary"
"NSAIDketo","Ankylosing Spondylitis","Primary"
"NSAIDketo","Gout","Primary"
"NSAIDketo","Lupus","Primary"
"NSAIDketo","Treatment failure on optimal doses of or intolerance to , ALL of the following: ibuprofen, naproxen (regular release), diclofenac, AND either celecoxib or meloxicam","Primary"
"NSAIDketo","Other",""
"NSAIDketoSR","Gout","Primary"
"NSAIDketoSR","Lupus","Primary"
"NSAIDketoSR","Treatment failure on optimal dose, or intolerance to, at least one of enteric-coated ASA, ibuprofen, or naproxen","Primary"
"NSAIDketoSR","Other",""
"NSAIDketoSR","Rheumatoid Arthritis","Primary"
"NSAIDketoSR","Psoriatic Arthritis","Primary"
"NSAIDketoSR","Ankylosing Spondylitis","Primary"
"OBE","Initial - Obeticholic acid will be used as monotherapy","Secondary"
"OBE","Renewal - For PBC, with supplemental details","Primary"
"OBE","Renewal - For PBC, with lab evidence","Primary"
"OBE","Other (exceptional)",""
"OBE","Initial - For treatment of adult patient with confirmed diagnosis of primary biliary cholangitis (PBC)","Primary"
"OBE","Initial - Obeticolic acid will be used in combination with ursodeoxycholic acid (UDCA)","Secondary"
"ocrelizumab","As treatment for Early Primary Progressive Multiple Sclerosis (PPMS)","Primary"
"ocrelizumab","Other",""
"ofloxacin","Failure or intolerance to first-line agents (e.g. aminoglycosides)","Primary"
"ofloxacin","Other",""
"olan","Other","Primary"
"olan","Used as an antiemetic for nausea (exceptional)","Primary"
"olan","Diagnosis of Schizophrenia AND treatment failure or intolerance to at least one other specified anti-psychotic agent","Primary"
"olan","Diagnosis of other psychosis (not dementia related) AND treatment failure or intolerance to at least one other specified anti-psychotic agent","Primary"
"olan","Diagnosis of Bipolar I disorder AND treatment failure or intolerance to lithium, carbamazepine or divalproex sodium AND treatment failure or intolerance to at least one other specified anti-psychotic agent","Primary"
"omalizumabPFS","Severe Allergic Asthma - initial","Primary"
"omalizumabPFS","Severe Allergic Asthma - renewal","Primary"
"omalizumabPFS","Other","Primary"
"omalizumabvial","Severe Allergic Asthma - initial","Primary"
"omalizumabvial","Chronic Spontaneous Urticaria (CSU) - initial","Primary"
"omalizumabvial","Chronic Spontaneous Urticaria (CSU) - renewal","Primary"
"omalizumabvial","Other","Primary"
"omalizumabvial","Severe Allergic Asthma - renewal","Primary"
"omnipod","Other form of diabetes (please specify):","Primary"
"omnipod","Type 1 diabetes","Primary"
"onabot","Diagnosis of migraines/hyperhydrosis - Not Approved","Primary"
"onabot","Treatment of blepharospasm.","Primary"
"onabot","Treatment of spasmodic torticollis / cervical dystonia","Primary"
"onabot","Treatment of overactive bladder (OAB) in adult patients","Primary"
"onabot","Treatment of strabismus","Primary"
"onabot","Treatment of equinus foot deformity due to spasticity in pediatric Cerebral Palsy patients 2 years of age or older.","Primary"
"onabot","Treatment of focal spasticity, including the treatment of upper limb spasticity associated with stroke in adults.","Primary"
"onabot","Treatment of urinary incontinence due to neurogenic detrusor overactivity (NDO) associated with multiple sclerosis or subcervical spinal cord injury,","Primary"
"onabot","Other","Primary"
"otherInsulinPumpNotApproved","Other form of diabetes (please specify):","Primary"
"otherInsulinPumpNotApproved","Type 1 diabetes","Primary"
"otherSAP","other",""
"ozanimod","Renewal - 1 year","Secondary"
"ozanimod","Initial - 14 weeks","Secondary"
"ozanimod","Ulcerative Colitis","Primary"
"ozurdex","Diabetic Macular Edema when submitted by a retinal specialist","Primary"
"ozurdex","Other (Not Approved)","Primary"
"Pagetsalen","Diagnosis of Paget's disease","Primary"
"Pagetsalen","Other",""
"Pagetsrise","diagnosis of Paget's disease","Primary"
"Pagetsrise","other",""
"PAH1","Other",""
"PAH1","For the treatment of World Health Organization (WHO) / New York Heart Association (NYHA) functional class III pulmonary arterial hypertension (PAH)","Primary"
"PAH2","As monotherapy, for the treatment of World Health Organization (WHO) / New York Heart Association (NYHA) functional class IV pulmonary arterial hypertension (PAH)","Primary"
"PAH2","other",""
"PAH2","As monotherapy, for the treatment of World Health Organization (WHO) / New York Heart Association (NYHA) functional class III pulmonary arterial hypertension (PAH)","Primary"
"PAH4","For the treatment of functional class IV pulmonary arterial hypertension (PAH) - contraindication to the non-prostanoid therapies","Primary"
"PAH4","For the treatment of functional class IV pulmonary arterial hypertension (PAH) - inadequate response to the non-prostanoid therapies","Primary"
"PAH4","Other",""
"PAH5","Adult patient with World Health Organization / New York Heart Association functional class III PAH whose symptoms are inadequately controlled with a phosphodiesterase-type 5 inhibitor and endothelin receptor antagonist:","Primary"
"PAH5","PAH associated with connective tissue disorders","Primary"
"PAH5","PAH associated with congenital heart disease","Primary"
"PAH5","Other",""
"PAH5","Idiopathic pulmonary arterial hypertension (PAH)","Primary"
"PAH5","Heritable PAH","Primary"
"pamidronate","Diagnosis indicating bone metastases associated with cancer (except breast cancer)","Primary"
"pamidronate","Other",""
"pentamidine","Other",""
"pentamidine","For PJP prophylaxis","Primary"
"pentazocine","Other",""
"pentazocine","Patient has experienced treatment failure or intolerance to at least two identified opioids","Primary"
"pentazocine","For pain management in a specified pain diagnosis","Primary"
"perampanel","Other",""
"perampanel","For adjunctive therapy (to be used in combination with at least ONE other anti-epileptic drug) for partial-onset seizures","Primary"
"perampanel","At least four other anti-epileptic medications have been tried without success","Primary"
"pimecro","Diagnosis of eczema - refractory to three months of potent topical corticosteroid therapy","Primary"
"pimecro","Diagnosis of eczema - intolerant to topical corticosteroid treatment","Primary"
"pimecro","Other",""
"pirfenidone","EXCEPTIONAL REQUEST: progressive pulmonary fibrosis (PPF)","Primary"
"pirfenidone","initial (7 months)","Secondary"
"pirfenidone","renewal (1 year)","Secondary"
"pirfenidone","mild to moderate idiopathic pulmonary fibrosis (IPF)","Primary"
"pirfenidone","Other","Primary"
"piroxicam","Rheumatoid Arthritis","Primary"
"piroxicam","Lupus","Primary"
"piroxicam","Treatment failure on optimal doses of or intolerance to , ALL of the following: ibuprofen, naproxen (regular release), diclofenac, AND either celecoxib or meloxicam","Primary"
"piroxicam","Psoriatic Arthritis","Primary"
"piroxicam","Other",""
"piroxicam","Gout","Primary"
"piroxicam","Ankylosing Spondylitis","Primary"
"prami","For the treatment of idiopathic Parkinson's disease - cannot tolerate or has contraindications to levodopa","Primary"
"prami","For the treatment of idiopathic Parkinson's disease - other","Primary"
"prami","Other",""
"prami","For the treatment of idiopathic Parkinson's disease - receiving treatment with levodopa and requires additional adjunctive therapy","Primary"
"prasugrel","Other","Primary"
"prasugrel","STEMI PLUS Stent PLUS Failure on Clopidogrel and ASA due to definite stent thrombosis or recurrent MI","Primary"
"prazosin","None","Primary"
"prazosin","Other","Primary"
"prazosin","Exceptional: management of nightmares due to PTSD","Primary"
"pregabalin","Renewal","Secondary"
"pregabalin","Initial","Secondary"
"propranolol","renewal - proliferating infantile┬áhemangioma requiring systemic therapy","Primary"
"propranolol","initial - proliferating infantile┬áhemangioma requiring systemic therapy","Primary"
"prostaglandin","Erectile dysfunction that occurs as a result of vascular or neurological damage that precludes adequate filling of the sinusoidal spaces","Primary"
"prostaglandin","Other",""
"prucalopride","Other","Primary"
"prucalopride","Exceptional request","Primary"
"ralox","Clinical or radiographically-documented fracture due to osteoporosis - intolerable side effects to a minimum 1 month trial of oral bisphosphonates, alendronate or risedronate","Primary"
"ralox","Other",""
"ralox","Clinical or radiographically-documented fracture due to osteoporosis - unsatisfactory clinical response, defined as a new fragility fracture after 1 year adherence to alendronate or alendronate plus cholecalciferol or risedronate therapy","Primary"
"ranibizumabCMPD","Clinically significant macular edema secondary to Branch Retinal Vein Occlusion (BRVO) or Central Retinal Vein Occlusion (CRVO)","Primary"
"ranibizumabCMPD","Diabetic Macular Degeneration (DME)","Primary"
"ranibizumabCMPD","Other (exceptional request)","Primary"
"ranibizumabCMPD","The patient experienced intolerance to bevacizumab treatment warranting discontinuation such as loss in visual acuity despite optimal treatment, sustained increase in intraocular pressure, endophthalmitis","Secondary"
"ranibizumabCMPD","Neovascular (Wet) Age-Related Macular Degeneration (nAMD)","Primary"
"ranibizumabCMPD","Disease activity is present at 3 consecutive   visits after administration of bevacizumab at a minimum of 4 week intervals with no signs of anatomic or functional improvement","Secondary"
"ranibizumabCMPD","The patient did not achieve an improvement of at least 15 Early Treatment Diabetes Retinopathy Study (ETDRS) letters despite 6 months of optimal treatment with bevacizumab","Secondary"
"ranibizumabCMPD","None","Primary"
"ranibizumabCMPD","The patient did not achieve any improvement  in their best corrected visual acuity (BCVA) score despite 3 consecutive courses of bevacizumab","Secondary"
"Rebif","As monotherapy for the treatment of relapsing-remitting multiple sclerosis - switch","Primary"
"Rebif","As monotherapy for the treatment of relapsing-remitting multiple sclerosis - initial","Primary"
"Rebif","As monotherapy for the treatment of relapsing-remitting multiple sclerosis - renewal","Primary"
"rifaximin","Other",""
"rifaximin","Reducing the risk of overt hepatic encephalopathy (HE) recurrence - unable to achieve adequate control despite taking the maximum tolerated dose of lactulose","Primary"
"rifaximin","Reducing the risk of overt hepatic encephalopathy (HE) recurrence - hospitalized with HE associated with cirrhosis of the live","Primary"
"riluzole","Other","Primary"
"riluzole","Amylotrophic Lateral Sclerosis (ALS) or Lou Gehrig's Disease","Primary"
"risan","renewal","Secondary"
"risan","Other",""
"risan","Crohn's Disease","Primary"
"risan","Plaque Psoriasis","Primary"
"risan","initial","Secondary"
"ritux","Granulomatosis with Polyangiitis (GPA) or Microscopic Polyangiitis (MPA)","Primary"
"ritux","Other",""
"ritux","Rheumatoid Arthritis","Primary"
"ritux","Multiple Sclerosis","Primary"
"ritux","Initial","Secondary"
"ritux","Renewal","Secondary"
"ritux","Idiopathic Thrombocytopenic Purpura (ITP)","Primary"
"ritux","Neuromyelitis Optica (NMO)","Primary"
"ritux","Myasthenia Gravis (MG)","Primary"
"romiplostim_250mcg","ITP (Immune thrombocytopenic purpura)","Primary"
"romiplostim_250mcg","Other","Primary"
"romiplostim_500mcg","ITP (Immune thrombocytopenic purpura)","Primary"
"romiplostim_500mcg","Other","Primary"
"romosozumab","Other","Primary"
"romosozumab","For the continuation of therapy for the treatment of osteoporosis in patients already on romosozumab who require additional therapy to complete 12 months of treatment","Primary"
"romosozumab","For the initiation of treatment of osteoporosis in patients","Primary"
"ropinirole","For the treatment of idiopathic Parkinson's disease - cannot tolerate or has contraindications to levodopa","Primary"
"ropinirole","For the treatment of idiopathic Parkinson's disease - receiving treatment with levodopa and requires additional adjunctive therapy","Primary"
"ropinirole","For the treatment of idiopathic Parkinson's disease - other","Primary"
"ropinirole","Other",""
"rotig","For the treatment of advanced stage ParkinsonΓÇÖs disease, when the patient is receiving treatment with levodopa AND requires additional adjunctive therapy","Primary"
"rotig","Other",""
"rufinamide","Other",""
"rufinamide","For the treatment of Lennox-Gastaut syndrome (LGS)","Primary"
"ruxolitinib","Renewal coverage for acute graft-versus-host disease (aGvHD) in adult and pediatric patients aged 12 years and older. Duration of coverage: 12 weeks","Primary"
"ruxolitinib","Exceptional initial coverage for aGvHD in adult and pediatric patients aged 12 years and older. Duration of coverage: 4 weeks","Primary"
"ruxolitinib","Initial coverage for chronic graft-versus-host disease (cGvHD) in adult and pediatric patients aged 12 years and older. Duration of coverage: 6 months","Primary"
"ruxolitinib","Other","Primary"
"ruxolitinib","Exceptional initial coverage for cGvHD for in adult and pediatric patients aged 12 years and older. Duration of coverage: 6 months","Primary"
"ruxolitinib","Renewal coverage for chronic graft-versus-host disease (cGvHD) in adult and pediatric patients aged 12 years and older. Duration of coverage: 6 months","Primary"
"ruxolitinib","Initial coverage for acute graft-versus-host disease (aGvHD) in adult and pediatric patients aged 12 years and older. Duration of coverage: 4 weeks","Primary"
"sapropterin","Initial Coverage - treatment of hyperphenylalaninemia (HPA) due to tetrahydrobiopterin-responsive (BH4-responsive) phenylketonuria (PKU)","Primary"
"sapropterin","Pregnant patient","Secondary"
"sapropterin","Renewal Coverage - treatment of hyperphenylalaninemia (HPA) due to tetrahydrobiopterin-responsive (BH4-responsive) phenylketonuria (PKU)","Primary"
"sapropterin","Other","Primary"
"sarilumab","renewal","Secondary"
"sarilumab","Other",""
"sarilumab","Rheumatoid Arthritis","Primary"
"sarilumab","initial","Secondary"
"satralizumab","Other","Primary"
"satralizumab","Neuromyelitis optica spectrum disorder (NMOSD)","Primary"
"secukinumab","renewal","Secondary"
"secukinumab","Psoriatic Arthritis","Primary"
"secukinumab","Ankylosing Spondylitis","Primary"
"secukinumab","initial","Secondary"
"secukinumab","Plaque Psoriasis","Primary"
"secukinumab","Other",""
"semaglutide","Type 2 diabetes - inadequate glycemic control with metformin","Primary"
"semaglutide","Other","Primary"
"semaglutide","Diagnosis of Obesity/Weight Loss Only - Not Approved","Primary"
"SGLT2","Type 2 diabetes - inadequate glycemic control with metformin","Primary"
"SGLT2","Other",""
"sildenafil","Other",""
"sildenafil","As monotherapy for the treatment of World Health Organization (WHO) / New York Heart Association (NYHA) functional class IV pulmonary arterial hypertension (PAH)","Primary"
"sildenafil","As monotherapy for the treatment of World Health Organization (WHO) / New York Heart Association (NYHA) functional class III pulmonary arterial hypertension (PAH)","Primary"
"silodosin","benign prostatic hyperplasia (BPH)",""
"siponimod","As monotherapy for the treatment of secondary progressive multiple sclerosis (SPMS) - initial","Primary"
"siponimod","Other","Primary"
"siponimod","As monotherapy for the treatment of secondary progressive multiple sclerosis (SPMS) - renewal","Primary"
"sirolimus","lymphangioleimyomatosis (LAM)","Primary"
"sirolimus","idiopathic thrombocytopenia (ITP)","Primary"
"sirolimus","Other","Primary"
"sirolimus","kaposiform hemangioendothelioma (KHE)","Primary"
"solifen","Who have developed SEVERE intolerance to immediate-release oxybutynin requiring discontinuation of oxybutynin","Primary"
"solifen","Overactive Bladder Syndrome","Primary"
"somatropin","For chronic renal insufficiency","Primary"
"somatropin","For true growth hormone deficiency┬á","Primary"
"somatropin","Other",""
"sovaldi","genotype 2 - Treatment-naive or treatment-experienced┬╣ with no cirrhosis or with compensated cirrhosis┬▓: (with RBV) for 12 weeks.","Primary"
"sovaldi","genotype 3 - Treatment-naive or treatment-experienced┬╣ with no cirrhosis or with compensated cirrhosis┬▓: (with RBV) for 24 weeks.","Primary"
"statinsfluv","Other",""
"statinsfluv","Results of trial to rosuvastatin┬á- Other","Primary"
"statinsfluv","Results of trial to atorvastatin - Intolerance","Primary"
"statinsfluv","Results of trial to atorvastatin - Other","Primary"
"statinsfluv","Results of trial to rosuvastatin┬á- Treatment failure","Primary"
"statinsfluv","Results of trial to atorvastatin - Treatment failure","Primary"
"statinsfluv","Results of trial to rosuvastatin┬á- Intolerance","Primary"
"statinslova","Treatment failure on optimal doses of, OR specified intolerance to BOTH reference drugs: atorvastatin AND rosuvastatin","Primary"
"statinslova","Other",""
"statinsprav","Treatment failure on optimal doses of, OR specified intolerance to BOTH reference drugs: atorvastatin AND rosuvastatin","Primary"
"statinsprav","Other",""
"statinssimv","Results of trial to atorvastatin - Intolerance","Primary"
"statinssimv","Results of trial to rosuvastatin┬á- Intolerance","Primary"
"statinssimv","Results of trial to rosuvastatin┬á- Other","Primary"
"statinssimv","Other",""
"statinssimv","Results of trial to atorvastatin - Treatment failure","Primary"
"statinssimv","Results of trial to rosuvastatin┬á- Treatment failure","Primary"
"statinssimv","Results of trial to atorvastatin - Other","Primary"
"stiripen","Diagnosis of severe myoclonic epilepsy in infancy (Dravet syndrome)","Primary"
"stiripen","Other",""
"Suboxone12-16excep","Exceptional review by pharmacist",""
"sulindac","Lupus","Primary"
"sulindac","Other",""
"sulindac","Rheumatoid Arthritis","Primary"
"sulindac","Psoriatic Arthritis","Primary"
"sulindac","Gout","Primary"
"sulindac","Ankylosing Spondylitis","Primary"
"sulindac","Treatment failure on optimal doses of or intolerance to , ALL of the following: ibuprofen, naproxen (regular release), diclofenac, AND either celecoxib or meloxicam","Primary"
"sumatrip","Oral absorption is not practical.","Primary"
"sumatrip","Nausea and vomiting prevents swallowing oral preparations","Primary"
"sumatrip","Other",""
"tacrotopical","Other","Primary"
"tacrotopical","Diagnosis of eczema AND is intolerant to topical corticosteroid treatment","Primary"
"tacrotopical","Diagnosis of eczema AND is refractory to three months of potent topical corticosteroid therapy","Primary"
"tacrotopical","Diagnosis of eczema AND the area affected includes the eyebrows and/or periorbital region","Primary"
"tadalafil","As monotherapy for the treatment of World Health Organization (WHO) / New York Heart Association (NYHA) functional class III pulmonary arterial hypertension (PAH)","Primary"
"tadalafil","Other",""
"tadalafil","As monotherapy for the treatment of World Health Organization (WHO) / New York Heart Association (NYHA) functional class IV pulmonary arterial hypertension (PAH)","Primary"
"tazarotene","For the topical treatment of acne vulgaris in patients 10 years of age and older","Primary"
"tazarotene","Other","Primary"
"tenofovir","Other - patient is pregnant; to reduce vertical transmission of Hepatitis B","Primary"
"tenofovir","Other - Hepatitis B reactivation prophylaxis while on immunosuppressant(s)","Primary"
"tenofovir","Other",""
"tenofovir","Viral breakthrough while on treatment (adefovir experienced with persistant viremia and lamivudine resistance)","Primary"
"tenofovir","Chronic Hepatitis B","Primary"
"tenofovir","Viral breakthrough while on treatment (lamivudine resistance)","Primary"
"tenoxicam","Gout","Primary"
"tenoxicam","Other",""
"tenoxicam","Lupus","Primary"
"tenoxicam","Treatment failure on optimal doses of or intolerance to , ALL of the following: ibuprofen, naproxen (regular release), diclofenac, AND either celecoxib or meloxicam","Primary"
"tenoxicam","Rheumatoid Arthritis","Primary"
"tenoxicam","Psoriatic Arthritis","Primary"
"tenoxicam","Ankylosing Spondylitis","Primary"
"terbinafine","Diagnosis of severe onychomycosis","Primary"
"terbinafine","Other",""
"teriflunomide","As monotherapy for the treatment of relapsing-remitting multiple sclerosis - initial","Primary"
"teriflunomide","As monotherapy for the treatment of relapsing-remitting multiple sclerosis - switch","Primary"
"teriflunomide","As monotherapy for the treatment of relapsing-remitting multiple sclerosis - renewal","Primary"
"teriparatide","Hyperparathyroidism (exceptional)","Primary"
"teriparatide","Osteoporosis (exceptional)","Primary"
"teriparatide","Other","Primary"
"testosteronecypi","For the treatment of testosterone deficiency in - hypogonadism","Primary"
"testosteronecypi","Other",""
"testosteronecypi","For the treatment of testosterone deficiency in - orchiectomy","Primary"
"testosteronecypi","For the treatment of testosterone deficiency in - undescended testes","Primary"
"testosteronecypi","For the treatment of testosterone deficiency in - Klinefelter's syndrome","Primary"
"testosteronecypi","For the treatment of testosterone deficiency in - female-to-male transformation","Primary"
"testosteronecypi","For the treatment of testosterone deficiency in - pituitary tumour","Primary"
"testosteronecypi","For the treatment of testosterone deficiency in - removal of pituitary gland","Primary"
"testosteronecypi","For the indication of documented low testosterone levels due to - surgery of pituitary gland","Primary"
"testosteronecypi","For the indication of documented low testosterone levels due to - AIDS-wasting syndrome","Primary"
"testosteroneenan","Other",""
"testosteroneenan","For the treatment of testosterone deficiency in - hypogonadism","Primary"
"testosteroneenan","For the treatment of testosterone deficiency in - undescended testes","Primary"
"testosteroneenan","For the treatment of testosterone deficiency in - orchiectomy","Primary"
"testosteroneenan","For the treatment of testosterone deficiency in - Klinefelter's syndrome","Primary"
"testosteroneenan","For the treatment of testosterone deficiency in - female-to-male transformation","Primary"
"testosteroneenan","For the treatment of testosterone deficiency in - pituitary tumour","Primary"
"testosteroneenan","For the treatment of testosterone deficiency in - removal of pituitary gland","Primary"
"testosteroneenan","For the indication of documented low testosterone levels due to - surgery of pituitary gland","Primary"
"testosteroneenan","For the indication of documented low testosterone levels due to - AIDS-wasting syndrome","Primary"
"testosteroneprop","For the treatment of testosterone deficiency in - pituitary tumour","Primary"
"testosteroneprop","Other",""
"testosteroneprop","For the indication of documented low testosterone levels due to - surgery of pituitary gland","Primary"
"testosteroneprop","For the treatment of testosterone deficiency in - removal of pituitary gland","Primary"
"testosteroneprop","For the treatment of testosterone deficiency in - hypogonadism","Primary"
"testosteroneprop","For the treatment of testosterone deficiency in - female-to-male transformation","Primary"
"testosteroneprop","For the indication of documented low testosterone levels due to - AIDS-wasting syndrome","Primary"
"testosteroneprop","For the treatment of testosterone deficiency in - undescended testes","Primary"
"testosteroneprop","For the treatment of testosterone deficiency in - orchiectomy","Primary"
"testosteroneprop","For the treatment of testosterone deficiency in - Klinefelter's syndrome","Primary"
"tezepelumab","Severe asthma","Primary"
"tezepelumab","Other","Primary"
"tiaprofenic","Psoriatic Arthritis","Primary"
"tiaprofenic","Ankylosing Spondylitis","Primary"
"tiaprofenic","Diagnosis of gout","Primary"
"tiaprofenic","Lupus","Primary"
"tiaprofenic","Other",""
"tiaprofenic","Treatment failure on optimal doses of or intolerance to , ALL of the following: ibuprofen, naproxen (regular release), diclofenac, AND either celecoxib or meloxicam","Primary"
"tiaprofenic","Rheumatoid Arthritis","Primary"
"ticag","Definite stent thrombosis after revascularization with percutaneous coronary intervention (PCI)","Primary"
"ticag","Recurrent unstable angina after revascularization with percutaneous coronary intervention (PCI)","Primary"
"ticag","Undergoing revascularization via percutaneous coronary intervention (PCI) secondary to ST or non-ST elevation myocardial infarction (STEMI or NSTEMI) or unstable angina","Primary"
"ticag","Recurrent ST or non-ST elevation myocardial infarction (STEMI or NSTEMI) after revascularization with percutaneous coronary intervention (PCI)","Primary"
"ticag","Other","Primary"
"ticlo","Secondary prevention of coronary, cerebral and peripheral vascular occlusion and embolization - intolerance to ASA","Primary"
"ticlo","Secondary prevention of coronary, cerebral and peripheral vascular occlusion and embolization - treatment failure with ASA","Primary"
"ticlo","Other",""
"tinzaparin","Other",""
"tinzaparin","C. - Treatment of venous thromboembolism associated with cancer","Primary"
"tinzaparin","A. - Treatment of venous thromboembolism","Primary"
"tinzaparin","B. - Prophylaxis of venous thromboembolism","Primary"
"tinzaparin","B. - Associated with pregnancy (up to 4 weeks post partum)","Secondary"
"tinzaparin","B. - Concurrent lupus anticoagulant syndrome, antiphospholipid syndrome or thrombophilia (3 months)","Secondary"
"tinzaparin","B. - Orthopedic surgery for major trauma (up to 10 days)","Secondary"
"tinzaparin","B. - Following total hip replacement surgery (35 days)","Secondary"
"tinzaparin","B. - Following total knee replacement surgery (14 days)","Secondary"
"tinzaparin","A. - Failure on oral anticoagulant therapy, ie. recurrence (up to 3 months)","Secondary"
"tinzaparin","Continued treatment from acute care for bridging INR (up to 10 days)","Secondary"
"tizan","Diagnosis of spasticity - intolerance to diazepam","Primary"
"tizan","Diagnosis of spasticity - treatment failure with diazepam","Primary"
"tizan","Diagnosis of spasticity - intolerance to baclofen","Primary"
"tizan","Diagnosis of spasticity - treatment failure with baclofen","Primary"
"tizan","Other",""
"tobi","Does not tolerate injectable forms of tobramycin to manage inhalation issues","Primary"
"tobi","Moderate to severe cystic fibrosis","Primary"
"tobi","Chronic pulmonary Pseudomonas aeruginosa infections","Primary"
"tobi","Other",""
"tobramycin300nebsExceptional","Non-Cystic Fibrosis indication: exceptional coverage of 300 mg / 5 mL nebules for inhalation","Primary"
"tobramycin300nebsExceptional","Other exceptional request","Primary"
"tociliz","initial","Secondary"
"tociliz","renewal","Secondary"
"tociliz","Rheumatoid Arthritis","Primary"
"tociliz","Neuromyelitis optica spectrum disorder (NMOSD)","Primary"
"tociliz","Polyarticular Juvenile Idiopathic Arthritis (pJIA)","Primary"
"tociliz","Giant Cell Arteritis (GCA)","Primary"
"tociliz","Systemic Juvenile Idiopathic Arthritis (sJIA)","Primary"
"tociliz","Other",""
"tofacitinib","Other",""
"tofacitinib","Rheumatoid Arthritis","Primary"
"tofacitinib","Ulcerative Colitis","Primary"
"tofacitinib","renewal","Secondary"
"tofacitinib","initial","Secondary"
"tretinoin","Other",""
"tretinoin","Diagnosis of skin cancer","Primary"
"tretinoin","Diagnosis of acne","Primary"
"trientine","Initial request: 1 year","Primary"
"trientine","Other",""
"trientine","Renewal request: 1 year","Primary"
"Twynsta","Other","Primary"
"Twynsta","Patient has experienced intractable cough or angioedema on an Angiotensin Converting Enzyme Inhibitor (ACE-I) AND is currently taking stable doses of both telmisartan and amlodipine","Primary"
"TZDpio","Type 2 diabetes - trial of one agent","Primary"
"TZDpio","Other",""
"TZDpio","Type 2 diabetes - Dual therapy of metformin and a sulfonylurea","Primary"
"TZDpio","Type 2 diabetes - Dual therapy of metformin and an insulin","Primary"
"upadacitinib","Switch","Secondary"
"upadacitinib","Initial","Secondary"
"upadacitinib","Moderate to Severe Crohn's disease","Primary"
"upadacitinib","Atopic Dermatitis","Primary"
"upadacitinib","Renewal","Secondary"
"upadacitinib","Fistulizing Crohn's disease","Primary"
"upadacitinib","Other",""
"uste","(NOT APPROVED) Fistulizing Crohn's","Primary"
"uste","(NOT APPROVED) Moderate to Severe Active Crohn's","Primary"
"uste","renewal","Secondary"
"uste","initial","Secondary"
"uste","Other",""
"uste","Hidradenitis Suppurativa","Primary"
"uste","Plaque Psoriasis","Primary"
"ustebiosimIVSC","Fistulizing Crohn’s - Initial","Primary"
"ustebiosimIVSC","Ulcerative Colitis - Initial","Primary"
"ustebiosimIVSC","Other",""
"ustebiosimIVSC","Moderate to Severe Active Crohn’s - Initial","Primary"
"ustebiosimSC","Plaque Psoriasis","Primary"
"ustebiosimSC","initial","Secondary"
"ustebiosimSC","Psoriatic Arthritis","Primary"
"ustebiosimSC","renewal","Secondary"
"ustebiosimSC","Moderate to Severe Active Crohn's","Primary"
"ustebiosimSC","Ulcerative Colitis","Primary"
"ustebiosimSC","Fistulizing Crohn's","Primary"
"ustebiosimSC","Other",""
"valganciclovir","For the prophylaxis of cytomegalovirus (CMV) infection post stem cell transplant, in patients who test positive for CMV upon polymerase chain reaction (PCR) laboratory testing.","Primary"
"valganciclovir","Other",""
"vancomycin","symptomatic C. Difficile Infection (CDI) - initiated on vancomycin as an inpatient (e.g. in a hospital setting, nursing home, or long-term care facility) and requires continuation","Primary"
"vancomycin","Patient has had recent approval, manually enter into PNP","Primary"
"vancomycin","Other","Primary"
"vancomycin","Treatment of symptomatic Clostridium Difficile Infection (CDI) - failed to respond to 4-6 days of oral metronidazole 500mg three times daily","Primary"
"vancomycin","Tapering request","Primary"
"vancomycin","symptomatic C. Difficile Infection (CDI) - symptoms of moderate to severe disease OR is experiencing a second disease recurrence (within 2-8 weeks of diagnosis of a previous episode)","Primary"
"vancomycin","Treatment of symptomatic Clostridium Difficile Infection (CDI) - intolerant or cannot take metronidazole (e.g., pregnant women, alcoholism)","Primary"
"varenicline","Patient has current NRT approval, no SA required","Primary"
"varenicline","NRT approval has an expiry date, Exceptional approval - NRT stopped due to side effects/treatment failure","Primary"
"vedoIV","renewal","Secondary"
"vedoIV","Moderate to Severe Active Crohn's","Primary"
"vedoIV","Fistulizing Crohn's","Primary"
"vedoIV","Ulcerative Colitis","Primary"
"vedoIV","initial","Secondary"
"vedoIV","renewal + escalation","Secondary"
"vericiquat","For treatment of symptomatic chronic heart failure (HF) in adult patients (≥18 years of age) with reduced ejection fraction who are stabilized after a recent decompensation event","Primary"
"voriconazole","For continuation of hospital-initiated treatment of culture proven invasive candidiasis with documented resistance to fluconazole","Primary"
"voriconazole","Other",""
"voriconazole","For continuation of hospital-initiated treatment of invasive aspergillosis","Primary"
"vortioxetine","For the treatment of Major Depressive Disorder (MDD) in adult patients PLUS treatment failure OR intolerance on at least TWO specified antidepressants","Primary"
"vortioxetine","Other",""
"vosevi","Genotype 5 - Previously treated with an NS5A inhibitor-containing regimen: sofosbuvir plus velpatasvir plus voxilaprevir for 12 weeks","Primary"
"vosevi","Genotype 2 - Previously treated with sofosbuvir containing regimen without an NS5A inhibitor: sofosbuvir plus velpatasvir plus voxilaprevir for 12 weeks.","Primary"
"vosevi","Genotype 2 - Previously treated with an NS5A inhibitor-containing regimen: sofosbuvir plus velpatasvir plus voxilaprevir for 12 weeks.","Primary"
"vosevi","Genotype 1 - Previously treated with sofosbuvir containing regimen without an NS5A inhibitor: sofosbuvir plus velpatasvir plus voxilaprevir for 12 weeks.","Primary"
"vosevi","Genotype 1 - Previously treated with an NS5A inhibitor-containing regimen: sofosbuvir plus velpatasvir plus voxilaprevir for 12 weeks.","Primary"
"vosevi","Genotype 3 - Previously treated with sofosbuvir containing regimen without an NS5A inhibitor: sofosbuvir plus velpatasvir plus voxilaprevir for 12 weeks.","Primary"
"vosevi","Genotype 3 - Exceptional Request: treatment na├»ve, F4 cirrhosis","Primary"
"vosevi","Genotype 3 - Previously treated with an NS5A inhibitor-containing regimen: sofosbuvir plus velpatasvir plus voxilaprevir for 12 weeks.","Primary"
"vosevi","Genotype 4 - Previously treated with an NS5A inhibitor-containing regimen: sofosbuvir plus velpatasvir plus voxilaprevir for 12 weeks.","Primary"
"vosevi","Genotype 4 - Previously treated with sofosbuvir containing regimen without an NS5A inhibitor: sofosbuvir plus velpatasvir plus voxilaprevir for 12 weeks.","Primary"
"vosevi","Unable to verify genotype - Previously treated with sofosbuvir containing regimen without an NS5A inhibitor: sofosbuvir plus velpatasvir plus voxilaprevir for 12 weeks.","Primary"
"vosevi","Genotype 6 - Previously treated with an NS5A inhibitor-containing regimen: sofosbuvir plus velpatasvir plus voxilaprevir for 12 weeks","Primary"
"vosevi","Unable to verify genotype - Previously treated with an NS5A inhibitor-containing regimen: sofosbuvir plus velpatasvir plus voxilaprevir for 12 weeks.","Primary"
"xgeva","Exceptional: Treatment of bony mets due to metastatic cancer","Primary"
"xgeva","Other","Primary"
"ypsoPump","Other form of diabetes (please specify):","Primary"
"ypsoPump","Type 1 diabetes","Primary"
"zepatier","Genotype 1a or 1b - treatment-experienced (prior relapsers): 12 weeks","Primary"
"zepatier","Genotype 1b - treatment-na├»ve: 12 weeks","Primary"
"zepatier","Genotype 4 - treatment-experienced (prior on-treatment virologic failures) with RBV: 16 weeks","Primary"
"zepatier","Genotype 1a - treatment-na├»ve: 12 weeks","Primary"
"zepatier","Genotype 4 - treatment-na├»ve: 12 weeks","Primary"
"zepatier","Genotype 1b - treatment-experienced (prior on-treatment virologic failures): 12 weeks","Primary"
"zepatier","Genotype 4 - treatment-experienced (prior relapsers): 12 weeks","Primary"
"zepatier","Genotype 1a - treatment-experienced (prior on-treatment virologic failures): 16 weeks","Primary"
"zip","Other psychosis (not dementia related) AND treatment failure or intolerance to at least one other specified anti-psychotic agent","Primary"
"zip","Diagnosis of schizophrenia AND treatment failure or intolerance to at least one other specified anti-psychotic agent","Primary"
"zip","Other",""
"zopiclone","For the treatment of insomnia - intolerant to, or failed on, at least three specified benzodiazepines","Primary"
"zopiclone","For the treatment of insomnia - intolerant to, or failed on, at least two specified benzodiazepines and one other specified hypnotic agent","Primary"
"zopiclone","Other","Primary"
"zopiclone","For the treatment of insomnia - HIV/AIDS","Primary"
"zopiclone","For the treatment of insomnia - identified psychiatric diagnosis","Primary"
"zopiclone","For the treatment of insomnia - history of drug or alcohol addiction","Primary"
"zopiclone","For the treatment of insomnia - fragile, elderly patient","Primary"
"zybanbupropion","Patient has current NRT approval, no SA required","Primary"
"zybanbupropion","NRT approval has an expiry date, Exceptional approval - NRT stopped due to side effects/treatment failure","Primary"
